Title,Decision,Decision_Date,PDF File,Application Date,Disease_Category,HT_Category
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer,Conditional,2025-02-19,Durvalumab_with_etoposide_and_either_carboplatin_or_cisplatin_for_untreated_extensive-stage_small-cell_lung_cancer.pdf,2024-08,Cancer,Drug
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer,Conditional,2025-02-19,Selpercatinib_for_previously_treated_RET_fusion-positive_advanced_non-small-cell_lung_cancer.pdf,2024-04,Cancer,Drug
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over,Rejected,2025-02-12,Ganaxolone_for_treating_seizures_caused_by_CDKL5_deficiency_disorder_in_people_2_years_and_over.pdf,,"Nervous System, Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over,Conditional,2025-02-12,Selpercatinib_for_advanced_thyroid_cancer_with_RET_alterations_after_treatment_with_a_targeted_cancer_drug_in_people_12_years_and_over.pdf,2024-04,Cancer,Drug
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over,Conditional,2025-02-12,Selpercatinib_for_advanced_thyroid_cancer_with_RET_alterations_untreated_with_a_targeted_cancer_drug_in_people_12_years_and_over.pdf,2023-10,Cancer,Drug
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy,Approved,2025-02-12,Olaparib_for_treating_BRCA_mutation-positive_HER2-negative_advanced_breast_cancer_after_chemotherapy.pdf,2024-06,Cancer,Drug
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer,Approved,2025-02-05,Pembrolizumab_for_adjuvant_treatment_of_resected_non-small-cell_lung_cancer.pdf,2024-03,Cancer,Drug
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment,Conditional,2025-02-05,Elacestrant_for_treating_oestrogen_receptor-positive_HER2-negative_advanced_breast_cancer_with_an_ESR1_mutation_after_endocrine_treatment.pdf,2024-05,Cancer,Drug
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease,Approved,2025-01-23,Vadadustat_for_treating_symptomatic_anaemia_in_adults_having_dialysis_for_chronic_kidney_disease.pdf,2024-04,Chronic,Drug
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal),Rejected,2025-01-22,Niraparib_with_abiraterone_acetate_and_prednisone_for_untreated_hormone-relapsed_metastatic_prostate_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours,Approved,2025-01-22,Anhydrous_sodium_thiosulfate_for_preventing_hearing_loss_caused_by_cisplatin_chemotherapy_in_people_1_month_to_17_years_with_localised_solid_tumours.pdf,2024-04,Cancer,Drug
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over,Approved,2025-01-16,Vamorolone_for_treating_Duchenne_muscular_dystrophy_in_people_4_years_and_over.pdf,2023-10,"Chronic, Rare Disease (Orphan Drugs), Musculoskeletal diseases",Drug
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal),Rejected,2025-01-15,Bimekizumab_for_treating_moderate_to_severe_hidradenitis_suppurativa_(terminated_appraisal).pdf,,Chronic,Drug
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal),Rejected,2025-01-15,Andexanet_alfa_for_reversing_anticoagulation_in_people_with_intracranial_haemorrhage_(terminated_appraisal).pdf,,"Cardiovascular, Nervous System",Drug
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer,Approved,2025-01-15,Durvalumab_with_chemotherapy_before_surgery_(neoadjuvant)_then_alone_after_surgery_(adjuvant)_for_treating_resectable_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban,Conditional,2021-05-12,Andexanet_alfa_for_reversing_anticoagulation_from_apixaban_or_rivaroxaban.pdf,,Cardiovascular,Drug
Tebentafusp for treating advanced uveal melanoma,Approved,2025-01-09,Tebentafusp_for_treating_advanced_uveal_melanoma.pdf,2021-11,"Cancer, Rare Disease (Orphan Drugs)",Drug
Tirzepatide for managing overweight and obesity,Conditional,2024-12-23,Tirzepatide_for_managing_overweight_and_obesity.pdf,,Chronic,Drug
Ublituximab for treating relapsing multiple sclerosis,Conditional,2024-12-18,Ublituximab_for_treating_relapsing_multiple_sclerosis.pdf,2024-08,Nervous System,Drug
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments,Approved,2024-12-11,Elranatamab_for_treating_relapsed_and_refractory_multiple_myeloma_after_3_or_more_treatments.pdf,2023-10,Cancer,Drug
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal),Rejected,2024-12-11,Toripalimab_with_chemotherapy_for_untreated_advanced_oesophageal_squamous_cell_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer,Conditional,2024-12-04,Crizotinib_for_treating_ROS1-positive_advanced_non-small-cell_lung_cancer.pdf,2024-05,Cancer,Drug
Bevacizumab gamma for treating wet age-related macular degeneration,Conditional,2024-12-04,Bevacizumab_gamma_for_treating_wet_age-related_macular_degeneration.pdf,2024-07,Nervous System,Drug
Eplontersen for treating hereditary transthyretin-related amyloidosis,Approved,2024-11-27,Eplontersen_for_treating_hereditary_transthyretin-related_amyloidosis.pdf,2024-02,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer,Approved,2024-11-20,Pembrolizumab_with_chemotherapy_before_surgery_(neoadjuvant)_then_alone_after_surgery_(adjuvant)_for_treating_resectable_non-small-cell_lung_cancer.pdf,2024-03,Cancer,Drug
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis,Conditional,2024-11-20,Fedratinib_for_treating_disease-related_splenomegaly_or_symptoms_in_myelofibrosis.pdf,2024-03,"Chronic, Rare Disease (Orphan Drugs)",Drug
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over,Approved,2024-11-20,Crovalimab_for_treating_paroxysmal_nocturnal_haemoglobinuria_in_people_12_years_and_over.pdf,2024-05,Rare Disease (Orphan Drugs),Drug
Elafibranor for previously treated primary biliary cholangitis,Approved,2024-11-14,Elafibranor_for_previously_treated_primary_biliary_cholangitis.pdf,2024-04,Rare Disease (Orphan Drugs),Drug
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer,Approved,2024-11-13,Alectinib_for_adjuvant_treatment_of_ALK-positive_non-small-cell_lung_cancer.pdf,2024-06,Cancer,Drug
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments,Approved,2024-11-13,Teclistamab_for_treating_relapsed_and_refractory_multiple_myeloma_after_3_or_more_treatments.pdf,,"Chronic, Cancer",Drug
Avapritinib for treating advanced systemic mastocytosis,Approved,2024-11-06,Avapritinib_for_treating_advanced_systemic_mastocytosis.pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria,Conditional,2024-10-23,Danicopan_with_ravulizumab_or_eculizumab_for_treating_paroxysmal_nocturnal_haemoglobinuria.pdf,2022-09,Rare Disease (Orphan Drugs),Drug
"Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia",Approved,2024-10-23,"Quizartinib_for_induction,_consolidation_and_maintenance_treatment_of_newly_diagnosed_FLT3-ITD-positive_acute_myeloid_leukaemia.pdf",2024-03,Cancer,Drug
Belzutifan for treating tumours associated with von Hippel-Lindau disease,Approved,2024-10-16,Belzutifan_for_treating_tumours_associated_with_von_Hippel-Lindau_disease.pdf,2023-06,"Cancer, Rare Disease (Orphan Drugs)",Drug
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension,Conditional,2024-10-02,Latanoprost–netarsudil_for_previously_treated_primary_open-angle_glaucoma_or_ocular_hypertension.pdf,2023-06,Chronic,Drug
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments,Approved,2024-09-25,Trifluridine–tipiracil_with_bevacizumab_for_treating_metastatic_colorectal_cancer_after_2_systemic_treatments.pdf,2023-12,Cancer,Drug
"Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Approved,2024-09-17,"Rucaparib_for_maintenance_treatment_of_relapsed_platinum-sensitive_ovarian,_fallopian_tube_or_peritoneal_cancer.pdf",,"Cancer, Obstetrics/Gynaecology",Drug
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal),Rejected,2024-09-12,Empagliflozin_for_treating_type_2_diabetes_in_people_10_to_17_years_(terminated_appraisal).pdf,,Chronic,Drug
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over,Approved,2024-09-11,Evinacumab_for_treating_homozygous_familial_hypercholesterolaemia_in_people_12_years_and_over.pdf,2023-05,"Cardiovascular, Rare Disease (Orphan Drugs)",Drug
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over,Conditional,2024-09-11,Exagamglogene_autotemcel_for_treating_transfusion-dependent_beta-thalassaemia_in_people_12_years_and_over.pdf,2023-06,Rare Disease (Orphan Drugs),Drug
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion,Approved,2024-09-11,Faricimab_for_treating_visual_impairment_caused_by_macular_oedema_after_retinal_vein_occlusion.pdf,,Nervous System,Drug
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Approved,2024-09-11,Futibatinib_for_previously_treated_advanced_cholangiocarcinoma_with_FGFR2_fusion_or_rearrangement.pdf,2024-02,"Cancer, Rare Disease (Orphan Drugs)",Drug
Iptacopan for treating paroxysmal nocturnal haemoglobinuria,Approved,2024-09-04,Iptacopan_for_treating_paroxysmal_nocturnal_haemoglobinuria.pdf,2023-10,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment,Approved,2024-09-04,Zanubrutinib_for_treating_marginal_zone_lymphoma_after_anti-CD20-based_treatment.pdf,2024-07,Cancer,Drug
Vibegron for treating symptoms of overactive bladder syndrome,Approved,2024-09-04,Vibegron_for_treating_symptoms_of_overactive_bladder_syndrome.pdf,2024-04,Urinary-Track Diseases,Drug
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma,Approved,2024-08-29,Pembrolizumab_with_platinum-_and_fluoropyrimidine-based_chemotherapy_for_untreated_advanced_HER2-negative_gastric_or_gastro-oesophageal_junction_adenocarcinoma.pdf,2023-09,Cancer,Drug
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer,Approved,2021-10-20,Pembrolizumab_with_platinum-_and_fluoropyrimidine-based_chemotherapy_for_untreated_advanced_oesophageal_and_gastro-oesophageal_junction_cancer.pdf,,Cancer,Drug
Risankizumab for treating moderately to severely active ulcerative colitis,Conditional,2024-08-22,Risankizumab_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,2023-11,Chronic,Drug
Relugolix for treating hormone-sensitive prostate cancer,Approved,2024-08-14,Relugolix_for_treating_hormone-sensitive_prostate_cancer.pdf,,Cancer,Drug
Linzagolix for treating moderate to severe symptoms of uterine fibroids,Conditional,2024-08-14,Linzagolix_for_treating_moderate_to_severe_symptoms_of_uterine_fibroids.pdf,2023-09,Obstetrics/Gynaecology,Drug
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal),Rejected,2024-08-08,Enzalutamide_for_treating_non-metastatic_prostate_cancer_after_radical_prostatectomy_or_radiotherapy_(terminated_appraisal).pdf,,Cancer,Drug
Abaloparatide for treating osteoporosis after menopause,Conditional,2024-08-07,Abaloparatide_for_treating_osteoporosis_after_menopause.pdf,2023-09,Musculoskeletal diseases,Drug
Burosumab for treating X-linked hypophosphataemia in adults,Approved,2024-08-07,Burosumab_for_treating_X-linked_hypophosphataemia_in_adults.pdf,,Rare Disease (Orphan Drugs),Drug
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy,Rejected,2024-07-29,Trastuzumab_deruxtecan_for_treating_HER2-low_metastatic_or_unresectable_breast_cancer_after_chemotherapy.pdf,2023-03,Cancer,Drug
"Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis",Approved,2024-07-24,"Ivacaftor–tezacaftor–elexacaftor,_tezacaftor–ivacaftor_and_lumacaftor–ivacaftor_for_treating_cystic_fibrosis.pdf",,"Chronic, Rare Disease (Orphan Drugs)",Drug
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B,Approved,2024-07-24,Etranacogene_dezaparvovec_for_treating_moderately_severe_or_severe_haemophilia_B.pdf,,Rare Disease (Orphan Drugs),Drug
Tenecteplase for treating acute ischaemic stroke,Approved,2024-07-24,Tenecteplase_for_treating_acute_ischaemic_stroke.pdf,2024-03,Nervous System,Drug
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over,Conditional,2024-07-10,Lebrikizumab_for_treating_moderate_to_severe_atopic_dermatitis_in_people_12_years_and_over.pdf,,Chronic,Drug
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal),Rejected,2024-07-10,Lisocabtagene_maraleucel_for_treating_relapsed_or_refractory_aggressive_B-cell_non-Hodgkin_lymphoma_(terminated_appraisal).pdf,,Cancer,Drug
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma,Conditional,2024-07-03,Selective_internal_radiation_therapy_with_QuiremSpheres_for_treating_unresectable_advanced_hepatocellular_carcinoma.pdf,2024-01,Cancer,Medical Device
Selective internal radiation therapies for treating hepatocellular carcinoma,Conditional,2021-03-31,Selective_internal_radiation_therapies_for_treating_hepatocellular_carcinoma.pdf,2019-05,Cancer,Other treatment
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy,Approved,2024-06-19,Tafamidis_for_treating_transthyretin_amyloidosis_with_cardiomyopathy.pdf,2023-09,"Cardiovascular, Chronic, Rare Disease (Orphan Drugs)",Drug
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal),Rejected,2024-06-13,Baricitinib_for_treating_juvenile_idiopathic_arthritis_in_people_2_years_and_over_(terminated_appraisal).pdf,,Musculoskeletal diseases,Drug
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma,Rejected,2024-06-12,Pembrolizumab_with_trastuzumab_and_chemotherapy_for_untreated_locally_advanced_unresectable_or_metastatic_HER2-positive_gastric_or_gastro-oesophageal_junction_adenocarcinoma.pdf,2023-05,Cancer,Drug
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation,Approved,2024-06-05,Ivosidenib_with_azacitidine_for_untreated_acute_myeloid_leukaemia_with_an_IDH1_R132_mutation.pdf,2023-09,Cancer,Drug
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal),Rejected,2024-06-05,Nivolumab_for_adjuvant_treatment_of_completely_resected_melanoma_at_high_risk_of_recurrence_in_people_12_years_and_over_(terminated_appraisal).pdf,,Cancer,Drug
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2024-05-29,Trastuzumab_deruxtecan_for_treating_HER2-mutated_advanced_non-small-cell_lung_cancer_after_platinum-based_chemotherapy_(terminated_appraisal).pdf,,Cancer,Drug
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over,Approved,2024-05-29,Dabrafenib_with_trametinib_for_treating_BRAF_V600E_mutation-positive_glioma_in_children_and_young_people_aged_1_year_and_over.pdf,2023-10,"Cancer, Nervous System",Drug
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal),Rejected,2024-05-29,Zanubrutinib_with_obinutuzumab_for_treating_relapsed_or_refractory_B-cell_follicular_lymphoma_after_2_or_more_treatments_(terminated_appraisal).pdf,,Cancer,Drug
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal),Rejected,2024-05-22,Sirolimus_for_treating_facial_angiofibroma_caused_by_tuberous_sclerosis_complex_in_people_6_years_and_over_(terminated_appraisal).pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis,Approved,2007-08-22,Natalizumab_for_the_treatment_of_adults_with_highly_active_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis,Approved,2014-05-28,Alemtuzumab_for_treating_highly_active_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Cladribine for treating relapsing–remitting multiple sclerosis,Conditional,2019-12-19,Cladribine_for_treating_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration,Rejected,2008-08-27,Ranibizumab_and_pegaptanib_for_the_treatment_of_age-related_macular_degeneration.pdf,,Chronic,Drug
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia,Conditional,2013-11-27,Ranibizumab_for_treating_choroidal_neovascularisation_associated_with_pathological_myopia.pdf,,Chronic,Drug
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion,Conditional,2013-05-22,Ranibizumab_for_treating_visual_impairment_caused_by_macular_oedema_secondary_to_retinal_vein_occlusion.pdf,,"Chronic, Nervous System",Drug
Atogepant for preventing migraine,Conditional,2024-05-15,Atogepant_for_preventing_migraine.pdf,,Nervous System,Drug
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma,Conditional,2024-05-15,Selinexor_with_bortezomib_and_dexamethasone_for_previously_treated_multiple_myeloma.pdf,2023-08,Cancer,Drug
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under,Approved,2024-05-15,Tisagenlecleucel_for_treating_relapsed_or_refractory_B-cell_acute_lymphoblastic_leukaemia_in_people_25 years_and_under.pdf,2023-10,"Cancer, Rare Disease (Orphan Drugs)",Drug
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments,Approved,2024-05-08,Selinexor_with_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_after_4_or_more_treatments.pdf,2023-07,"Cancer, Chronic",Drug
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19,Rejected,2024-05-08,Remdesivir_and_tixagevimab_plus_cilgavimab_for_treating_COVID-19.pdf,,NULL,Drug
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over,Conditional,2024-05-01,Pembrolizumab_for_treating_relapsed_or_refractory_classical_Hodgkin_lymphoma_in_people_3_years_and_over.pdf,2023-09,Cancer,Drug
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma,Rejected,2018-09-03,Pembrolizumab_for_treating_relapsed_or_refractory_classical_Hodgkin_lymphoma.pdf,2017-09,Cancer,Drug
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal),Rejected,2024-04-30,Gefapixant_for_treating_refractory_or_unexplained_chronic_cough_(terminated_appraisal).pdf,,Chronic,Drug
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2024-04-25,Melphalan_flufenamide_with_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal),Rejected,2024-04-24,Pembrolizumab_with_gemcitabine_and_cisplatin_for_untreated_advanced_biliary_tract_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma,Conditional,2024-04-10,Cabozantinib_with_nivolumab_for_untreated_advanced_renal_cell_carcinoma.pdf,2023-04,Cancer,Drug
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Approved,2024-04-03,Dostarlimab_with_platinum-based_chemotherapy_for_treating_advanced_or_recurrent_endometrial_cancer_with_high_microsatellite_instability_or_mismatch_repair_deficiency.pdf,,"Cancer, Obstetrics/Gynaecology",Drug
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal),Rejected,2024-03-28,Sebelipase_alfa_for_treating_lysosomal_acid_lipase_deficiency_that_is_not_Wolman_disease_(terminated_appraisal).pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
"Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy",Approved,2024-03-28,"Olaparib_for_maintenance_treatment_of_BRCA_mutation-positive_advanced_ovarian,_fallopian_tube_or_peritoneal_cancer_after_response_to_first-line_platinum-based_chemotherapy.pdf",2023-09,"Cancer, Obstetrics/Gynaecology",Drug
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal),Rejected,2024-03-28,Human_alpha1-proteinase_inhibitor_for_treating_emphysema_(terminated_appraisal).pdf,,Chronic,Drug
Ritlecitinib for treating severe alopecia areata in people 12 years and over,Approved,2024-03-27,Ritlecitinib_for_treating_severe_alopecia_areata_in_people_12_years_and_over.pdf,,Rare Disease (Orphan Drugs),Drug
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis,Conditional,2024-03-27,Daratumumab_in_combination_for_treating_newly_diagnosed_systemic_amyloid_light-chain_amyloidosis.pdf,2021-06,Rare Disease (Orphan Drugs),Drug
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal),Rejected,2024-03-27,Satralizumab_for_preventing_relapses_in_neuromyelitis_optica_spectrum_disorders_(terminated_appraisal).pdf,,"Chronic, Nervous System, Rare Disease (Orphan Drugs)",Drug
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms,Conditional,2024-03-20,Momelotinib_for_treating_myelofibrosis-related_splenomegaly_or_symptoms.pdf,2023-08,"Chronic, Rare Disease (Orphan Drugs)",Drug
"Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19",Conditional,2023-03-29,"Nirmatrelvir_plus_ritonavir,_sotrovimab_and_tocilizumab_for_treating_COVID-19.pdf",,NULL,Drug
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema,Conditional,2024-03-13,Fluocinolone_acetonide_intravitreal_implant_for_treating_chronic_diabetic_macular_oedema.pdf,2023-10,Chronic,Medical Device
Dupilumab for treating moderate to severe prurigo nodularis,Rejected,2024-03-13,Dupilumab_for_treating_moderate_to_severe_prurigo_nodularis.pdf,,Rare Disease (Orphan Drugs),Drug
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over,Approved,2024-03-11,Etrasimod_for_treating_moderately_to_severely_active_ulcerative_colitis_in_people_aged_16_and_over.pdf,2023-09,Chronic,Drug
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Conditional,2024-03-06,Epcoritamab_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_after_2_or_more_systemic_treatments.pdf,2023-04,Cancer,Drug
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations,Approved,2024-02-21,Talazoparib_for_treating_HER2-negative_advanced_breast_cancer_with_germline_BRCA_mutations.pdf,,Cancer,Drug
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over,Conditional,2024-02-07,Belumosudil_for_treating_chronic_graft-versus-host_disease_after_2_or_more_systemic_treatments_in_people_12_years_and_over.pdf,,"Chronic, Rare Disease (Orphan Drugs)",Drug
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over,Conditional,2024-02-07,Nivolumab–relatlimab_for_untreated_unresectable_or_metastatic_melanoma_in_people_12_years_and_over.pdf,2023-04,Cancer,Drug
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer,Approved,2024-02-07,Olaparib_with_abiraterone_for_untreated_hormone-relapsed_metastatic_prostate_cancer.pdf,2023-04,Cancer,Drug
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments,Conditional,2024-01-31,Loncastuximab_tesirine_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_and_high-grade_B-cell_lymphoma_after_2_or_more_systemic_treatments.pdf,,Cancer,Drug
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments,Approved,2024-01-31,Ivosidenib_for_treating_advanced_cholangiocarcinoma_with_an_IDH1_R132_mutation_after_1_or_more_systemic_treatments.pdf,2023-04,Cancer,Drug
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal),Rejected,2024-01-30,Treosulfan_with_fludarabine_before_allogeneic_stem_cell_transplant_for_people_aged_1_month_to_17_years_with_non-malignant_diseases_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
"Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Approved,2024-01-17,"Olaparib_with_bevacizumab_for_maintenance_treatment_of_advanced_high-grade_epithelial_ovarian,_fallopian_tube_or_primary_peritoneal_cancer.pdf",2022-11,"Cancer, Obstetrics/Gynaecology",Drug
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer,Approved,2024-01-10,Durvalumab_with_gemcitabine_and_cisplatin_for_treating_unresectable_or_advanced_biliary_tract_cancer.pdf,2023-02,Cancer,Drug
Targeted-release budesonide for treating primary IgA nephropathy,Conditional,2023-12-20,Targeted-release_budesonide_for_treating_primary_IgA_nephropathy.pdf,2023-04,Urinary-Track Diseases,Drug
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal),Rejected,2023-12-20,Ravulizumab_for_treating_generalised_myasthenia_gravis_(terminated_appraisal).pdf,2022-11,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal),Rejected,2023-12-20,Ravulizumab_for_treating_AQP4_antibody-positive_neuromyelitis_optica_spectrum_disorder_(terminated_appraisal).pdf,,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Empagliflozin for treating chronic kidney disease,Conditional,2023-12-20,Empagliflozin_for_treating_chronic_kidney_disease.pdf,,"Chronic, Urinary-Track Diseases",Drug
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes,Rejected,2023-12-19,Hybrid_closed_loop_systems_for_managing_blood_glucose_levels_in_type_1_diabetes.pdf,,Chronic,Medical Device
Risdiplam for treating spinal muscular atrophy,Conditional,2021-12-16,Risdiplam_for_treating_spinal_muscular_atrophy.pdf,2020-10,"Nervous System, Rare Disease (Orphan Drugs), Musculoskeletal diseases",Drug
"Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer",Conditional,2023-12-13,"Pembrolizumab_plus_chemotherapy_with_or_without_bevacizumab_for_persistent,_recurrent_or_metastatic_cervical_cancer.pdf",2023-05,Cancer,Drug
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal),Rejected,2023-12-07,Dupilumab_for_treating_eosinophilic_oesophagitis_in_people_12_years_and_over_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Secukinumab for treating moderate to severe hidradenitis suppurativa,Conditional,2023-12-06,Secukinumab_for_treating_moderate_to_severe_hidradenitis_suppurativa.pdf,2022-12,Chronic,Drug
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal),Rejected,2023-11-30,Idecabtagene_vicleucel_for_treating_relapsed_and_refractory_multiple_myeloma_after_3_or_more_treatments_(terminated_appraisal).pdf,,Cancer,Drug
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal),Rejected,2023-11-29,Tisagenlecleucel_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_after_2_or_more_systemic_therapies_(terminated_appraisal).pdf,,Cancer,Drug
Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms,Conditional,2023-11-29,Foslevodopa–foscarbidopa_for_treating_advanced_Parkinson’s_with_motor_symptoms.pdf,2022-08,"Nervous System, Chronic",Drug
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal),Rejected,2023-11-23,Decitabine–cedazuridine_for_untreated_acute_myeloid_leukaemia_when_intensive_chemotherapy_is_unsuitable_(terminated_appraisal).pdf,,Cancer,Drug
Zanubrutinib for treating chronic lymphocytic leukaemia,Conditional,2023-11-22,Zanubrutinib_for_treating_chronic_lymphocytic_leukaemia.pdf,2023-02,"Chronic, Cancer",Drug
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments,Rejected,2023-11-15,Lutetium-177_vipivotide_tetraxetan_for_treating_PSMA-positive_hormone-relapsed_metastatic_prostate_cancer_after_2_or_more_treatments.pdf,,Cancer,Drug
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction,Approved,2023-11-01,Empagliflozin_for_treating_chronic_heart_failure_with_preserved_or_mildly_reduced_ejection_fraction.pdf,,"Cardiovascular, Chronic",Drug
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine,Rejected,2023-11-01,Cabozantinib_for_previously_treated_advanced_differentiated_thyroid_cancer_unsuitable_for_or_refractory_to_radioactive_iodine.pdf,2022-09,Cancer,Drug
Ranibizumab for treating diabetic macular oedema,Rejected,2013-02-27,Ranibizumab_for_treating_diabetic_macular_oedema.pdf,,Chronic,Drug
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable,Approved,2023-10-25,Daratumumab_with_lenalidomide_and_dexamethasone_for_untreated_multiple_myeloma_when_a_stem_cell_transplant_is_unsuitable.pdf,2022-05,"Cancer, Chronic",Drug
Tirzepatide for treating type 2 diabetes,Conditional,2023-10-25,Tirzepatide_for_treating_type_2_diabetes.pdf,,Chronic,Drug
Baricitinib for treating severe alopecia areata,Rejected,2023-10-25,Baricitinib_for_treating_severe_alopecia_areata.pdf,2022-08,Rare Disease (Orphan Drugs),Drug
Mirikizumab for treating moderately to severely active ulcerative colitis,Conditional,2023-10-25,Mirikizumab_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,2022-12,Chronic,Drug
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal),Rejected,2023-10-19,Tabelecleucel_for_treating_post-transplant_lymphoproliferative_disorder_caused_by_the_Epstein-Barr_virus_(terminated_appraisal).pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Rimegepant for treating migraine,Conditional,2023-10-18,Rimegepant_for_treating_migraine.pdf,2022-06,Nervous System,Drug
Tofacitinib for treating active ankylosing spondylitis,Conditional,2023-10-18,Tofacitinib_for_treating_active_ankylosing_spondylitis.pdf,2021-11,Musculoskeletal diseases,Drug
Ruxolitinib for treating polycythaemia vera,Approved,2023-10-18,Ruxolitinib_for_treating_polycythaemia_vera.pdf,2022-10,Rare Disease (Orphan Drugs),Drug
Daridorexant for treating long-term insomnia,Conditional,2023-10-18,Daridorexant_for_treating_long-term_insomnia.pdf,2022-07,Nervous System,Drug
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Approved,2023-10-17,Glofitamab_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_after_2_or_more_systemic_treatments.pdf,,Cancer,Drug
Bimekizumab for treating axial spondyloarthritis,Conditional,2023-10-11,Bimekizumab_for_treating_axial_spondyloarthritis.pdf,,Musculoskeletal diseases,Drug
Pegunigalsidase alfa for treating Fabry disease,Conditional,2023-10-04,Pegunigalsidase_alfa_for_treating_Fabry_disease.pdf,2023-01,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Bimekizumab for treating active psoriatic arthritis,Conditional,2023-10-04,Bimekizumab_for_treating_active_psoriatic_arthritis.pdf,,Musculoskeletal diseases,Drug
"Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency",Approved,2023-09-20,"Pembrolizumab_for_previously_treated_endometrial,_biliary,_colorectal,_gastric_or_small_intestine_cancer_with_high_microsatellite_instability_or_mismatch_repair_deficiency.pdf",2023-01,Cancer,Drug
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy,Conditional,2023-09-06,Mavacamten_for_treating_symptomatic_obstructive_hypertrophic_cardiomyopathy.pdf,2022-06,"Cardiovascular, Chronic",Drug
Semaglutide for managing overweight and obesity,Conditional,2023-03-08,Semaglutide_for_managing_overweight_and_obesity.pdf,,Chronic,Drug
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease,Conditional,2023-08-15,Cipaglucosidase_alfa_with_miglustat_for_treating_late-onset_Pompe_disease.pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs), Musculoskeletal diseases",Drug
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer,Conditional,2023-07-26,Selpercatinib_for_untreated_RET_fusion-positive_advanced_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal),Rejected,2023-07-13,Semaglutide_for_managing_overweight_and_obesity_in_young_people_aged_12_to_17_years_(terminated_appraisal).pdf,,Chronic,Drug
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer,Rejected,2023-07-12,Lorlatinib_for_untreated_ALK-positive_advanced_non-small-cell_lung_cancer.pdf,2022-05,Cancer,Drug
Rimegepant for preventing migraine,Conditional,2023-07-05,Rimegepant_for_preventing_migraine.pdf,2022-06,Nervous System,Drug
"Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy",Conditional,2023-07-05,"Olaparib_for_maintenance_treatment_of_relapsed,_platinum-sensitive_ovarian,_fallopian_tube_or_peritoneal_cancer_after_2_or_more_courses_of_platinum-based_chemotherapy.pdf",,"Cancer, Obstetrics/Gynaecology",Drug
Deucravacitinib for treating moderate to severe plaque psoriasis,Conditional,2023-06-28,Deucravacitinib_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2022-04,Chronic,Drug
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction,Approved,2023-06-21,Dapagliflozin_for_treating_chronic_heart_failure_with_preserved_or_mildly_reduced_ejection_fraction.pdf,2022-09,"Cardiovascular, Chronic",Drug
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer,Approved,2023-06-21,Darolutamide_with_androgen_deprivation_therapy_and_docetaxel_for_treating_hormone-sensitive_metastatic_prostate_cancer.pdf,2022-09,Cancer,Drug
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer,Approved,2023-06-21,Pembrolizumab_with_lenvatinib_for_previously_treated_advanced_or_recurrent_endometrial_cancer.pdf,,"Cancer, Obstetrics/Gynaecology",Drug
Upadacitinib for previously treated moderately to severely active Crohn’s disease,Conditional,2023-06-21,Upadacitinib_for_previously_treated_moderately_to_severely_active_Crohn’s_disease.pdf,2022-10,Chronic,Drug
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal),Rejected,2023-06-20,Cemiplimab_for_treating_recurrent_or_metastatic_cervical_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer,Conditional,2023-06-14,Dabrafenib_plus_trametinib_for_treating_BRAF_V600_mutation-positive_advanced_non-small-cell_lung_cancer.pdf,2022-08,Cancer,Drug
Tixagevimab plus cilgavimab for preventing COVID-19,Rejected,2023-06-14,Tixagevimab_plus_cilgavimab_for_preventing_COVID-19.pdf,2022-11,NULL,Drug
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma,Rejected,2023-06-07,Axicabtagene_ciloleucel_for_treating_relapsed_or_refractory_follicular_lymphoma.pdf,2022-01,Cancer,Drug
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy,Conditional,2023-06-07,Axicabtagene_ciloleucel_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma_after_first-line_chemoimmunotherapy.pdf,2022-03,Cancer,Drug
Bulevirtide for treating chronic hepatitis D,Conditional,2023-06-07,Bulevirtide_for_treating_chronic_hepatitis_D.pdf,2022-04,Chronic,Drug
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over,Conditional,2023-06-07,Brexucabtagene_autoleucel_for_treating_relapsed_or_refractory_B-cell_acute_lymphoblastic_leukaemia_in_people_26_years_and_over.pdf,2021-11,"Cancer, Rare Disease (Orphan Drugs)",Drug
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma,Conditional,2023-06-06,Daratumumab_with_bortezomib_and_dexamethasone_for_previously_treated_multiple_myeloma.pdf,,Cancer,Drug
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal),Rejected,2023-06-06,Esketamine_for_treating_major_depressive_disorder_in_adults_at_imminent_risk_of_suicide_(terminated_appraisal).pdf,,Nervous System,Drug
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia,Conditional,2023-05-31,Ibrutinib_with_venetoclax_for_untreated_chronic_lymphocytic_leukaemia.pdf,,"Chronic, Cancer",Drug
Mosunetuzumab for treating relapsed or refractory follicular lymphoma,Rejected,2023-05-31,Mosunetuzumab_for_treating_relapsed_or_refractory_follicular_lymphoma.pdf,2022-05,Cancer,Drug
Risankizumab for previously treated moderately to severely active Crohn's disease,Conditional,2023-05-17,Risankizumab_for_previously_treated_moderately_to_severely_active_Crohn's_disease.pdf,2022-06,Chronic,Drug
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2023-05-17,Ciltacabtagene_autoleucel_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Difelikefalin for treating pruritus in people having haemodialysis,Approved,2023-05-17,Difelikefalin_for_treating_pruritus_in_people_having_haemodialysis.pdf,,Chronic,Drug
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy,Approved,2023-05-10,Olaparib_for_adjuvant_treatment_of_BRCA_mutation-positive_HER2-negative_high-risk_early_breast_cancer_after_chemotherapy.pdf,,Cancer,Drug
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,Approved,2023-05-10,Olaparib_for_previously_treated_BRCA_mutation-positive_hormone-relapsed_metastatic_prostate_cancer.pdf,,Cancer,Drug
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments,Rejected,2023-05-03,Ripretinib_for_treating_advanced_gastrointestinal_stromal_tumour_after_3_or_more_treatments.pdf,2022-05,Cancer,Drug
Voclosporin with mycophenolate mofetil for treating lupus nephritis,Approved,2023-05-03,Voclosporin_with_mycophenolate_mofetil_for_treating_lupus_nephritis.pdf,2022-05,"Chronic, Urinary-Track Diseases",Drug
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma,Rejected,2023-05-03,Tafasitamab_with_lenalidomide_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma.pdf,2022-05,Cancer,Drug
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal),Rejected,2023-05-03,Capmatinib_for_treating_advanced_non-small-cell_lung_cancer_with_MET_exon_14_skipping_(terminated_appraisal).pdf,,Cancer,Drug
Tezepelumab for treating severe asthma,Conditional,2023-04-20,Tezepelumab_for_treating_severe_asthma.pdf,,Chronic,Drug
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal),Rejected,2023-04-06,Trastuzumab_deruxtecan_for_treating_HER2-positive_unresectable_or_metastatic_gastric_or_gastro-oesophageal_junction_cancer_after_anti-HER2_treatment_(terminated_appraisal).pdf,,Cancer,Drug
Finerenone for treating chronic kidney disease in type 2 diabetes,Conditional,2023-03-23,Finerenone_for_treating_chronic_kidney_disease_in_type_2_diabetes.pdf,2022-01,"Chronic, Urinary-Track Diseases",Drug
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer,Approved,2023-03-22,Nivolumab_with_chemotherapy_for_neoadjuvant_treatment_of_resectable_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Eptinezumab for preventing migraine,Conditional,2023-03-01,Eptinezumab_for_preventing_migraine.pdf,2022-08,Nervous System,Drug
Cannabidiol for treating seizures caused by tuberous sclerosis complex,Conditional,2023-03-01,Cannabidiol_for_treating_seizures_caused_by_tuberous_sclerosis_complex.pdf,2022-06,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma,Conditional,2023-03-01,Polatuzumab_vedotin_in_combination_for_untreated_diffuse_large_B-cell_lymphoma.pdf,2022-03,Cancer,Drug
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Conditional,2023-02-28,Axicabtagene_ciloleucel_for_treating_diffuse_large_B-cell_lymphoma_and_primary_mediastinal_large_B-cell_lymphoma_after_2_or_more_systemic_therapies.pdf,,Cancer,Drug
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma,Conditional,2023-02-22,Ixazomib_with_lenalidomide_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma.pdf,2021-10,Cancer,Drug
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal),Rejected,2023-02-16,Mitapivat_for_treating_pyruvate_kinase_deficiency_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Vutrisiran for treating hereditary transthyretin-related amyloidosis,Approved,2023-02-15,Vutrisiran_for_treating_hereditary_transthyretin-related_amyloidosis.pdf,2022-10,"Rare Disease (Orphan Drugs), Nervous System",Drug
"Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",Conditional,2023-02-08,"Nivolumab_with_fluoropyrimidine-_and_platinum-based_chemotherapy_for_untreated_unresectable_advanced,_recurrent,_or_metastatic_oesophageal_squamous_cell_carcinoma.pdf",2022-03,Cancer,Drug
Regorafenib for previously treated metastatic colorectal cancer,Approved,2023-02-08,Regorafenib_for_previously_treated_metastatic_colorectal_cancer.pdf,2022-05,Cancer,Drug
Upadacitinib for treating active non-radiographic axial spondyloarthritis,Conditional,2023-02-01,Upadacitinib_for_treating_active_non-radiographic_axial_spondyloarthritis.pdf,2022-05,Musculoskeletal diseases,Drug
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,Approved,2023-02-01,Trastuzumab_deruxtecan_for_treating_HER2-positive_unresectable_or_metastatic_breast_cancer_after_1_or_more_anti-HER2_treatments.pdf,2022-04,Cancer,Drug
Somatrogon for treating growth disturbance in children and young people aged 3 years and over,Approved,2023-02-01,Somatrogon_for_treating_growth_disturbance_in_children_and_young_people_aged_3_years_and_over.pdf,,Rare Disease (Orphan Drugs),Drug
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,Conditional,2023-02-01,Nintedanib_for_treating_idiopathic_pulmonary_fibrosis_when_forced_vital_capacity_is_above_80%_predicted.pdf,2022-06,"Chronic, Rare Disease (Orphan Drugs)",Drug
Maribavir for treating refractory cytomegalovirus infection after transplant,Conditional,2023-01-18,Maribavir_for_treating_refractory_cytomegalovirus_infection_after_transplant.pdf,,Rare Disease (Orphan Drugs),Drug
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal),Rejected,2023-01-16,Angiotensin_II_for_treating_vasosuppressor-resistant_hypotension_caused_by_septic_or_distributive_shock_(terminated_appraisal).pdf,,Cardiovascular,Drug
"Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",Approved,2023-01-11,"Nivolumab_with_platinum-_and_fluoropyrimidine-based_chemotherapy_for_untreated_HER2-negative_advanced_gastric,_gastro-oesophageal_junction_or_oesophageal_adenocarcinoma.pdf",2021-02,Cancer,Drug
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma,Conditional,2023-01-11,Lenvatinib_with_pembrolizumab_for_untreated_advanced_renal_cell_carcinoma.pdf,2021-11,Cancer,Drug
Upadacitinib for treating moderately to severely active ulcerative colitis,Approved,2023-01-04,Upadacitinib_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,2022-04,Chronic,Drug
Avatrombopag for treating primary chronic immune thrombocytopenia,Approved,2022-12-15,Avatrombopag_for_treating_primary_chronic_immune_thrombocytopenia.pdf,2021-09,Rare Disease (Orphan Drugs),Drug
Cabozantinib for previously treated advanced hepatocellular carcinoma,Conditional,2022-12-14,Cabozantinib_for_previously_treated_advanced_hepatocellular_carcinoma.pdf,2022-02,Cancer,Drug
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Rejected,2022-12-14,Amivantamab_for_treating_EGFR_exon_20_insertion_mutation-positive_advanced_non-small-cell_lung_cancer_after_platinum-based_chemotherapy.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,Approved,2022-12-14,Pembrolizumab_for_neoadjuvant_and_adjuvant_treatment_of_triple-negative_early_or_locally_advanced_breast_cancer.pdf,2021-11,Cancer,Drug
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,Approved,2022-12-14,Trifluridine–tipiracil_for_treating_metastatic_gastric_cancer_or_gastro-oesophageal_junction_adenocarcinoma_after_2_or_more_treatments.pdf,2019-06,Cancer,Drug
Esketamine nasal spray for treatment-resistant depression,Rejected,2022-12-14,Esketamine_nasal_spray_for_treatment-resistant_depression.pdf,2019-07,Nervous System,Drug
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal),Rejected,2022-12-01,Cemiplimab_for_untreated_PD-L1-positive_advanced_or_metastatic_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal),Rejected,2022-11-29,Mepolizumab_for_treating_eosinophilic_granulomatosis_with_polyangiitis_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal),Rejected,2022-11-29,Mepolizumab_for_treating_severe_hypereosinophilic_syndrome_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2022-11-29,Mepolizumab_for_treating_severe_chronic_rhinosinusitis_with_nasal_polyps_(terminated_appraisal).pdf,,Chronic,Drug
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal),Rejected,2022-11-24,Luspatercept_for_treating_anaemia_caused_by_myelodysplastic_syndromes_(terminated_appraisal).pdf,,"Chronic, Rare Disease (Orphan Drugs)",Drug
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal),Rejected,2022-11-24,Luspatercept_for_treating_anaemia_caused_by_beta-thalassaemia_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2022-11-22,Carfilzomib_with_daratumumab_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal),Rejected,2022-11-22,Tisagenlecleucel_for_treating_follicular_lymphoma_after_2_or_more_therapies_(terminated_appraisal).pdf,,Cancer,Drug
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal),Rejected,2022-11-16,Ruxolitinib_for_treating_acute_graft_versus_host_disease_refractory_to_corticosteroids_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
"Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids 
 (terminated appraisal)",Rejected,2022-11-16,"Ruxolitinib_for_treating_chronic_graft_versus_host_disease_refractory_to_corticosteroids_
_(terminated_appraisal).pdf",,Chronic,Drug
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal),Rejected,2022-11-02,Slow-release_potassium_bicarbonate–potassium_citrate_for_treating_distal_renal_tubular_acidosis_(terminated_appraisal).pdf,2021-11,Urinary-Track Diseases,Drug
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma,Conditional,2022-10-26,Pembrolizumab_for_adjuvant_treatment_of_resected_stage_2B_or_2C_melanoma.pdf,2022-02,Cancer,Drug
"Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2022-10-26,"Palbociclib_with_fulvestrant_for_treating_hormone_receptor-positive,_HER2-negative_advanced_breast_cancer_after_endocrine_therapy.pdf",2019-04,Cancer,Drug
Pembrolizumab for adjuvant treatment of renal cell carcinoma,Conditional,2022-10-19,Pembrolizumab_for_adjuvant_treatment_of_renal_cell_carcinoma.pdf,2021-11,Cancer,Drug
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids,Approved,2022-10-19,Relugolix–estradiol–norethisterone_acetate_for_treating_moderate_to_severe_symptoms_of_uterine_fibroids.pdf,2021-10,Obstetrics/Gynaecology,Drug
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia,Conditional,2022-10-19,Zanubrutinib_for_treating_Waldenstrom’s_macroglobulinaemia.pdf,2021-03,"Cancer, Rare Disease (Orphan Drugs)",Drug
Fostamatinib for treating refractory chronic immune thrombocytopenia,Conditional,2022-10-19,Fostamatinib_for_treating_refractory_chronic_immune_thrombocytopenia.pdf,,Rare Disease (Orphan Drugs),Drug
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal),Rejected,2022-10-12,SQ_HDM_SLIT_for_treating_allergic_rhinitis_and_allergic_asthma_caused_by_house_dust_mites_(terminated_appraisal).pdf,,Chronic,Drug
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy,Approved,2022-10-05,Oral_azacitidine_for_maintenance_treatment_of_acute_myeloid_leukaemia_after_induction_therapy.pdf,2021-12,Cancer,Drug
Ozanimod for treating moderately to severely active ulcerative colitis,Conditional,2022-10-05,Ozanimod_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,,Chronic,Drug
Upadacitinib for treating active ankylosing spondylitis,Conditional,2022-09-30,Upadacitinib_for_treating_active_ankylosing_spondylitis.pdf,2021-11,Musculoskeletal diseases,Drug
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer,Approved,2022-09-28,Atezolizumab_for_adjuvant_treatment_of_resected_non-small-cell_lung_cancer.pdf,2021-10,Cancer,Drug
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis,Conditional,2022-09-21,Avacopan_for_treating_severe_active_granulomatosis_with_polyangiitis_or_microscopic_polyangiitis.pdf,,Rare Disease (Orphan Drugs),Drug
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal),Rejected,2022-09-21,Vedolizumab_for_treating_chronic_refractory_pouchitis_after_surgery_for_ulcerative_colitis_(terminated_appraisal).pdf,,Chronic,Drug
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal),Rejected,2022-09-14,Melphalan_for_haematological_diseases_before_allogeneic_haematopoietic_stem_cell_transplant_(terminated_appraisal).pdf,,Cancer,Drug
Dexamethasone intravitreal implant for treating diabetic macular oedema,Conditional,2022-09-14,Dexamethasone_intravitreal_implant_for_treating_diabetic_macular_oedema.pdf,2022-01,Chronic,Drug
Brolucizumab for treating diabetic macular oedema,Conditional,2022-08-31,Brolucizumab_for_treating_diabetic_macular_oedema.pdf,2022-03,Chronic,Drug
Avalglucosidase alfa for treating Pompe disease,Conditional,2022-08-24,Avalglucosidase_alfa_for_treating_Pompe_disease.pdf,2021-11,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies,Conditional,2022-08-17,Sacituzumab_govitecan_for_treating_unresectable_triple-negative_advanced_breast_cancer_after_2_or_more_therapies.pdf,2021-09,Cancer,Drug
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma,Conditional,2022-08-17,Nivolumab_with_ipilimumab_for_untreated_unresectable_malignant_pleural_mesothelioma.pdf,,Cancer,Drug
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-08-10,Guselkumab_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,,"Chronic, Musculoskeletal diseases",Drug
"Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",Conditional,2022-08-10,"Alpelisib_with_fulvestrant_for_treating_hormone_receptor-positive,_HER2-negative,_PIK3CA-mutated_advanced_breast_cancer.pdf",2021-07,Cancer,Drug
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence,Conditional,2022-08-10,Nivolumab_for_adjuvant_treatment_of_invasive_urothelial_cancer_at_high_risk_of_recurrence.pdf,2021-06,"Cancer, Urinary-Track Diseases",Drug
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer,Rejected,2022-08-03,Pralsetinib_for_treating_RET_fusion-positive_advanced_non-small-cell_lung_cancer.pdf,2021-08,Cancer,Drug
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,Conditional,2022-08-03,Asciminib_for_treating_chronic_myeloid_leukaemia_after_2_or_more_tyrosine_kinase_inhibitors.pdf,,Cancer,Drug
"Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis",Conditional,2022-08-03,"Abrocitinib,_tralokinumab_or_upadacitinib_for_treating_moderate_to_severe_atopic_dermatitis.pdf",2021-02,Chronic,Drug
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal),Rejected,2022-07-27,Duvelisib_for_treating_relapsed_or_refractory_chronic_lymphocytic_leukaemia_after_2_or_more_treatments_(terminated_appraisal).pdf,,Cancer,Drug
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease,Approved,2022-07-20,Imlifidase_for_desensitisation_treatment_before_kidney_transplant_in_people_with_chronic_kidney_disease.pdf,2020-09,"Chronic, Urinary-Track Diseases",Drug
"Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",Approved,2022-07-20,"Abemaciclib_with_endocrine_therapy_for_adjuvant_treatment_of_hormone_receptor-positive,_HER2-negative,_node-positive_early_breast_cancer_at_high_risk_of_recurrence.pdf",2021-11,Cancer,Drug
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-07-13,Risankizumab_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,2022-02,"Chronic, Musculoskeletal diseases",Drug
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides,Conditional,2022-07-13,Icosapent_ethyl_with_statin_therapy_for_reducing_the_risk_of_cardiovascular_events_in_people_with_raised_triglycerides.pdf,2021-10,"Cardiovascular, Chronic",Drug
Belimumab for treating lupus nephritis (terminated appraisal),Rejected,2022-07-13,Belimumab_for_treating_lupus_nephritis_(terminated_appraisal).pdf,,"Chronic, Urinary-Track Diseases",Drug
Roxadustat for treating symptomatic anaemia in chronic kidney disease,Conditional,2022-07-13,Roxadustat_for_treating_symptomatic_anaemia_in_chronic_kidney_disease.pdf,2021-06,"Chronic, Urinary-Track Diseases",Drug
Fenfluramine for treating seizures associated with Dravet syndrome,Conditional,2022-07-08,Fenfluramine_for_treating_seizures_associated_with_Dravet_syndrome.pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs), Nervous System",Drug
Teduglutide for treating short bowel syndrome,Conditional,2022-06-30,Teduglutide_for_treating_short_bowel_syndrome.pdf,,Rare Disease (Orphan Drugs),Drug
Faricimab for treating diabetic macular oedema,Conditional,2022-06-29,Faricimab_for_treating_diabetic_macular_oedema.pdf,2021-10,Chronic,Drug
Faricimab for treating wet age-related macular degeneration,Conditional,2022-06-29,Faricimab_for_treating_wet_age-related_macular_degeneration.pdf,2021-11,Nervous System,Drug
"Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",Conditional,2022-06-29,"Pembrolizumab_plus_chemotherapy_for_untreated,_triple-negative,_locally_recurrent_unresectable_or_metastatic_breast_cancer.pdf",2021-01,Cancer,Drug
Cemiplimab for treating advanced cutaneous squamous cell carcinoma,Conditional,2022-06-29,Cemiplimab_for_treating_advanced_cutaneous_squamous_cell_carcinoma.pdf,2022-01,Cancer,Drug
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,Conditional,2022-06-22,Durvalumab_for_maintenance_treatment_of_unresectable_non-small-cell_lung_cancer_after_platinum-based_chemoradiation.pdf,2022-01,Cancer,Drug
Venetoclax for treating chronic lymphocytic leukaemia,Approved,2022-06-15,Venetoclax_for_treating_chronic_lymphocytic_leukaemia.pdf,2021-11,Cancer,Drug
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal),Rejected,2022-06-15,Enfortumab_vedotin_for_previously_treated_locally_advanced_or_metastatic_urothelial_cancer_(terminated_appraisal).pdf,,"Urinary-Track Diseases, Cancer",Drug
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal),Rejected,2022-06-08,Anifrolumab_for_treating_active_autoantibody-positive_systemic_lupus_erythematosus_(terminated_appraisal).pdf,,Chronic,Drug
Diroximel fumarate for treating relapsing–remitting multiple sclerosis,Conditional,2022-06-08,Diroximel_fumarate_for_treating_relapsing–remitting_multiple_sclerosis.pdf,2021-11,Nervous System,Drug
Ibrutinib for treating Waldenstrom’s macroglobulinaemia,Rejected,2022-06-08,Ibrutinib_for_treating_Waldenstrom’s_macroglobulinaemia.pdf,2021-07,"Cancer, Rare Disease (Orphan Drugs)",Drug
Filgotinib for treating moderately to severely active ulcerative colitis,Approved,2022-06-01,Filgotinib_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,,Chronic,Drug
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal),Rejected,2022-05-25,TYRX_Absorbable_Antibacterial_Envelope_for_preventing_infection_from_cardiac_implantable_electronic_devices_(terminated_appraisal).pdf,,Cardiovascular,Medical Device
Romosozumab for treating severe osteoporosis,Conditional,2022-05-25,Romosozumab_for_treating_severe_osteoporosis.pdf,2021-06,Musculoskeletal diseases,Drug
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations,Conditional,2022-05-18,Tepotinib_for_treating_advanced_non-small-cell_lung_cancer_with_MET_gene_alterations.pdf,2021-08,Cancer,Drug
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy,Conditional,2022-05-11,Avelumab_for_maintenance_treatment_of_locally_advanced_or_metastatic_urothelial_cancer_after_platinum-based_chemotherapy.pdf,2020-10,"Cancer, Urinary-Track Diseases",Drug
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,Conditional,2022-04-27,Tucatinib_with_trastuzumab_and_capecitabine_for_treating_HER2-positive_advanced_breast_cancer_after_2_or_more_anti-HER2_therapies.pdf,2021-04,Cancer,Drug
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Conditional,2022-04-27,Venetoclax_with_low_dose_cytarabine_for_untreated_acute_myeloid_leukaemia_when_intensive_chemotherapy_is_unsuitable.pdf,,Cancer,Drug
"Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Conditional,2022-04-20,"Niraparib_for_maintenance_treatment_of_relapsed,_platinum-sensitive_ovarian,_fallopian_tube_and_peritoneal_cancer.pdf",,Cancer,Drug
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal),Rejected,2022-04-20,Nivolumab_with_cabozantinib_for_untreated_advanced_renal_cell_carcinoma_(terminated_appraisal).pdf,,Cancer,Drug
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma,Conditional,2022-04-13,Daratumumab_monotherapy_for_treating_relapsed_and_refractory_multiple_myeloma.pdf,2021-10,Cancer,Drug
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,Conditional,2022-03-30,Sotorasib_for_previously_treated_KRAS_G12C_mutation-positive_advanced_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal),Rejected,2022-03-30,Tagraxofusp_for_treating_blastic_plasmacytoid_dendritic_cell_neoplasm_(terminated_appraisal).pdf,,"Cancer, Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma,Approved,2022-03-24,Nivolumab_with_ipilimumab_for_untreated_advanced_renal_cell_carcinoma.pdf,2021-09,Cancer,Drug
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2022-03-16,Dostarlimab_for_previously_treated_advanced_or_recurrent_endometrial_cancer_with_high_microsatellite_instability_or_mismatch_repair_deficiency.pdf,,Cancer,Drug
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal),Rejected,2022-03-09,Lenalidomide_for_relapsed_or_refractory_mantle_cell_lymphoma_(terminated_appraisal).pdf,,Cancer,Drug
Empagliflozin for treating chronic heart failure with reduced ejection fraction,Conditional,2022-03-09,Empagliflozin_for_treating_chronic_heart_failure_with_reduced_ejection_fraction.pdf,,"Cardiovascular, Chronic",Drug
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea,Rejected,2022-03-09,Pitolisant_hydrochloride_for_treating_excessive_daytime_sleepiness_caused_by_obstructive_sleep_apnoea.pdf,2020-05,Chronic,Drug
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea,Rejected,2022-03-09,Solriamfetol_for_treating_excessive_daytime_sleepiness_caused_by_obstructive_sleep_apnoea.pdf,2020-05,"Chronic, Nervous System",Drug
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria,Conditional,2022-03-09,Pegcetacoplan_for_treating_paroxysmal_nocturnal_haemoglobinuria.pdf,2021-05,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Dapagliflozin for treating chronic kidney disease,Conditional,2022-03-09,Dapagliflozin_for_treating_chronic_kidney_disease.pdf,2021-04,"Chronic, Urinary-Track Diseases",Drug
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,Conditional,2022-02-23,Pembrolizumab_for_treating_relapsed_or_refractory_classical_Hodgkin_lymphoma_after_stem_cell_transplant_or_at_least_2_previous_therapies.pdf,2020-09,Cancer,Drug
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer,Conditional,2022-02-09,Pembrolizumab_with_carboplatin_and_paclitaxel_for_untreated_metastatic_squamous_non-small-cell_lung_cancer.pdf,2020-02,Cancer,Drug
"Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)",Rejected,2022-02-09,"Daratumumab_with_bortezomib,_melphalan_and_prednisone_for_untreated_multiple_myeloma_(terminated_appraisal).pdf",,Cancer,Drug
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable,Conditional,2022-02-02,Daratumumab_in_combination_for_untreated_multiple_myeloma_when_a_stem_cell_transplant_is_suitable.pdf,2020-09,Cancer,Drug
Fremanezumab for preventing migraine,Conditional,2022-02-02,Fremanezumab_for_preventing_migraine.pdf,2019-04,Nervous System,Drug
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Conditional,2022-02-02,Venetoclax_with_azacitidine_for_untreated_acute_myeloid_leukaemia_when_intensive_chemotherapy_is_unsuitable.pdf,,Cancer,Drug
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma,Conditional,2022-02-02,Pembrolizumab_for_adjuvant_treatment_of_completely_resected_stage_3_melanoma.pdf,2021-08,Cancer,Drug
Ponesimod for treating relapsing–remitting multiple sclerosis,Conditional,2022-02-02,Ponesimod_for_treating_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2022-02-02,Upadacitinib_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,,"Chronic, Musculoskeletal diseases",Drug
Palforzia for treating peanut allergy in children and young people,Approved,2022-02-02,Palforzia_for_treating_peanut_allergy_in_children_and_young_people.pdf,2021-05,Rare Disease (Orphan Drugs),Drug
Sodium zirconium cyclosilicate for treating hyperkalaemia,Conditional,2019-09-04,Sodium_zirconium_cyclosilicate_for_treating_hyperkalaemia.pdf,,Cardiovascular,Drug
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,Conditional,2022-01-19,Osimertinib_for_adjuvant_treatment_of_EGFR_mutation-positive_non-small-cell_lung_cancer_after_complete_tumour_resection.pdf,,Cancer,Drug
Cabotegravir with rilpivirine for treating HIV-1,Approved,2022-01-05,Cabotegravir_with_rilpivirine_for_treating_HIV-1.pdf,2021-02,Chronic,Drug
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy,Conditional,2022-01-05,Solriamfetol_for_treating_excessive_daytime_sleepiness_caused_by_narcolepsy.pdf,2020-01,Nervous System,Drug
Belimumab for treating active autoantibody-positive systemic lupus erythematosus,Conditional,2021-12-15,Belimumab_for_treating_active_autoantibody-positive_systemic_lupus_erythematosus.pdf,2020-11,Chronic,Drug
Cenobamate for treating focal onset seizures in epilepsy,Conditional,2021-12-15,Cenobamate_for_treating_focal_onset_seizures_in_epilepsy.pdf,2020-12,Nervous System,Drug
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome,Conditional,2021-12-15,Mogamulizumab_for_previously_treated_mycosis_fungoides_and_Sézary_syndrome.pdf,2020-01,"Cancer, Rare Disease (Orphan Drugs)",Drug
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2021-12-08,Olaparib_for_maintenance_treatment_of_BRCA_mutation-positive_metastatic_pancreatic_cancer_after_platinum-based_chemotherapy_(terminated_appraisal).pdf,,Cancer,Drug
Dupilumab for treating severe asthma with type 2 inflammation,Conditional,2021-12-08,Dupilumab_for_treating_severe_asthma_with_type_2_inflammation.pdf,,Chronic,Drug
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders,Conditional,2021-12-01,Mexiletine_for_treating_the_symptoms_of_myotonia_in_non-dystrophic_myotonic_disorders.pdf,2019-12,"Chronic, Nervous System, Rare Disease (Orphan Drugs)",Drug
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal),Rejected,2021-12-01,Liraglutide_for_managing_obesity_in_people_aged_12_to_17_years_(terminated_appraisal).pdf,,Chronic,Drug
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer,Conditional,2021-11-17,Nivolumab_for_adjuvant_treatment_of_resected_oesophageal_or_gastro-oesophageal_junction_cancer.pdf,2021-03,Cancer,Drug
Nintedanib for treating progressive fibrosing interstitial lung diseases,Approved,2021-11-17,Nintedanib_for_treating_progressive_fibrosing_interstitial_lung_diseases.pdf,,Rare Disease (Orphan Drugs),Drug
Upadacitinib for treating moderate rheumatoid arthritis,Conditional,2021-11-10,Upadacitinib_for_treating_moderate_rheumatoid_arthritis.pdf,,Musculoskeletal diseases,Drug
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal),Rejected,2021-11-10,NBTXR-3_for_treating_advanced_soft_tissue_sarcoma_(terminated_appraisal).pdf,,Cancer,Drug
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer,Conditional,2021-10-28,Apalutamide_with_androgen_deprivation_therapy_for_treating_high-risk_hormone-relapsed_non-metastatic_prostate_cancer.pdf,2020-07,Cancer,Drug
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer,Conditional,2021-10-28,Apalutamide_with_androgen_deprivation_therapy_for_treating_hormone-sensitive_metastatic_prostate_cancer.pdf,2020-07,Cancer,Drug
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable,Conditional,2021-10-27,Atezolizumab_for_untreated_PD-L1-positive_advanced_urothelial_cancer_when_cisplatin_is_unsuitable.pdf,2021-05,"Cancer, Urinary-Track Diseases",Drug
Tofacitinib for treating juvenile idiopathic arthritis,Conditional,2021-10-20,Tofacitinib_for_treating_juvenile_idiopathic_arthritis.pdf,2021-02,Musculoskeletal diseases,Drug
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Conditional,2021-10-20,Nivolumab_for_treating_recurrent_or_metastatic_squamous_cell_carcinoma_of_the_head_and_neck_after_platinum-based_chemotherapy.pdf,2020-02,Cancer,Drug
Berotralstat for preventing recurrent attacks of hereditary angioedema,Conditional,2021-10-20,Berotralstat_for_preventing_recurrent_attacks_of_hereditary_angioedema.pdf,2020-12,Rare Disease (Orphan Drugs),Drug
Secukinumab for treating moderate to severe plaque psoriasis in children and young people,Conditional,2021-10-07,Secukinumab_for_treating_moderate_to_severe_plaque_psoriasis_in_children_and_young_people.pdf,2021-02,Chronic,Drug
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal),Rejected,2021-10-06,Baloxavir_marboxil_for_treating_acute_uncomplicated_influenza_(terminated_appraisal).pdf,,NULL,Drug
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia,Conditional,2021-10-06,Inclisiran_for_treating_primary_hypercholesterolaemia_or_mixed_dyslipidaemia.pdf,2020-10,"Cardiovascular, Chronic",Drug
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal),Rejected,2021-09-29,Avapritinib_for_treating_unresectable_or_metastatic_gastrointestinal_stromal_tumours_(terminated_appraisal).pdf,2020-04,"Cancer, Rare Disease (Orphan Drugs)",Drug
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal),Rejected,2021-09-29,Vericiguat_for_treating_chronic_heart_failure_with_reduced_ejection_fraction_(terminated_appraisal).pdf,,"Cardiovascular, Chronic",Drug
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2021-09-22,Daratumumab_with_pomalidomide_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2021-09-22,Isatuximab_with_carfilzomib_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Midostaurin for treating advanced systemic mastocytosis,Conditional,2021-09-22,Midostaurin_for_treating_advanced_systemic_mastocytosis.pdf,2020-03,Rare Disease (Orphan Drugs),Drug
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria,Conditional,2021-09-22,Sapropterin_for_treating_hyperphenylalaninaemia_in_phenylketonuria.pdf,2020-07,Rare Disease (Orphan Drugs),Drug
"Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2021-09-15,"Abemaciclib_with_fulvestrant_for_treating_hormone_receptor-positive,_HER2-negative_advanced_breast_cancer_after_endocrine_therapy.pdf",,Cancer,Drug
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer,Rejected,2021-09-08,Nivolumab_with_ipilimumab_and_chemotherapy_for_untreated_metastatic_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Bimekizumab for treating moderate to severe plaque psoriasis,Conditional,2021-09-01,Bimekizumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2021-01,Chronic,Drug
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Conditional,2021-08-25,Pemigatinib_for_treating_relapsed_or_refractory_advanced_cholangiocarcinoma_with_FGFR2_fusion_or_rearrangement.pdf,2020-08,"Cancer, Rare Disease (Orphan Drugs)",Drug
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome,Approved,2008-03-26,Continuous_positive_airway_pressure_for_the_treatment_of_obstructive_sleep_apnoea/hypopnoea_syndrome.pdf,,Chronic,Medical Device
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma,Conditional,2021-08-18,Chlormethine_gel_for_treating_mycosis_fungoides-type_cutaneous_T-cell_lymphoma.pdf,2020-01,"Cancer, Rare Disease (Orphan Drugs)",Drug
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,Rejected,2021-08-18,Abiraterone_for_treating_newly_diagnosed_high-risk_hormone-sensitive_metastatic_prostate_cancer.pdf,2018-03,Cancer,Drug
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2021-07-28,Nivolumab_with_ipilimumab_for_previously_treated_metastatic_colorectal_cancer_with_high_microsatellite_instability_or_mismatch_repair_deficiency.pdf,2020-10,Cancer,Drug
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal),Rejected,2021-07-21,Duvelisib_for_treating_relapsed_follicular_lymphoma_after_2_or_more_systemic_therapies_(terminated_appraisal).pdf,,Cancer,Drug
Ixekizumab for treating axial spondyloarthritis,Conditional,2021-07-21,Ixekizumab_for_treating_axial_spondyloarthritis.pdf,2020-05,Musculoskeletal diseases,Drug
Secukinumab for treating non-radiographic axial spondyloarthritis,Conditional,2021-07-21,Secukinumab_for_treating_non-radiographic_axial_spondyloarthritis.pdf,2019-12,Musculoskeletal diseases,Drug
"Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed",Rejected,2021-07-14,"Adalimumab,_etanercept,_infliximab_and_abatacept_for_treating_moderate_rheumatoid_arthritis_after_conventional_DMARDs_have_failed.pdf",,Musculoskeletal diseases,Drug
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal),Rejected,2021-07-14,Dasatinib_for_treating_Philadelphia-chromosome-positive_acute_lymphoblastic_leukaemia_(terminated_appraisal).pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Enzalutamide for treating hormone-sensitive metastatic prostate cancer,Approved,2021-07-07,Enzalutamide_for_treating_hormone-sensitive_metastatic_prostate_cancer.pdf,2019-11,Cancer,Drug
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy,Conditional,2021-07-07,Nivolumab_for_advanced_non-squamous_non-small-cell_lung_cancer_after_chemotherapy.pdf,,Cancer,Drug
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation,Approved,2013-02-27,Apixaban_for_preventing_stroke_and_systemic_embolism_in_people_with_non-valvular_atrial_fibrillation.pdf,,"Cardiovascular, Chronic",Drug
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation,Approved,2015-09-23,Edoxaban_for_preventing_stroke_and_systemic_embolism_in_people_with_non-valvular_atrial_fibrillation.pdf,,Cardiovascular,Drug
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis,Approved,2021-06-23,Budesonide_orodispersible_tablet_for_inducing_remission_of_eosinophilic_oesophagitis.pdf,2019-09,Rare Disease (Orphan Drugs),Drug
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Conditional,2021-06-23,Pembrolizumab_for_untreated_metastatic_colorectal_cancer_with_high_microsatellite_instability_or_mismatch_repair_deficiency.pdf,2020-09,Cancer,Drug
Ravulizumab for treating atypical haemolytic uraemic syndrome,Approved,2021-06-23,Ravulizumab_for_treating_atypical_haemolytic_uraemic_syndrome.pdf,,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer,Conditional,2021-06-15,Nivolumab_for_previously_treated_unresectable_advanced_or_recurrent_oesophageal_cancer.pdf,2020-04,Cancer,Drug
Ozanimod for treating relapsing–remitting multiple sclerosis,Rejected,2021-06-09,Ozanimod_for_treating_relapsing–remitting_multiple_sclerosis.pdf,2019-11,Nervous System,Drug
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer,Approved,2021-06-02,Atezolizumab_monotherapy_for_untreated_advanced_non-small-cell_lung_cancer.pdf,2020-09,Cancer,Drug
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal),Rejected,2021-05-26,Ibrutinib_with_obinutuzumab_for_untreated_chronic_lymphocytic_leukaemia_and_small_lymphocytic_lymphoma_(terminated_appraisal).pdf,,Cancer,Drug
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal),Rejected,2021-05-26,Ibrutinib_with_rituximab_for_untreated_chronic_lymphocytic_leukaemia_(terminated_appraisal).pdf,,"Cancer, Chronic",Drug
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,Conditional,2021-05-26,Trastuzumab_deruxtecan_for_treating_HER2-positive_unresectable_or_metastatic_breast_cancer_after_2_or_more_anti-HER2_therapies.pdf,2020-08,Cancer,Drug
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria,Approved,2021-05-19,Ravulizumab_for_treating_paroxysmal_nocturnal_haemoglobinuria.pdf,2020-09,"Rare Disease (Orphan Drugs), Ultra-Rare Disease (Ultra Orphan Drugs)",Drug
Ofatumumab for treating relapsing multiple sclerosis,Conditional,2021-05-19,Ofatumumab_for_treating_relapsing_multiple_sclerosis.pdf,2020-08,Nervous System,Drug
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal),Rejected,2021-05-19,Crisaborole_for_treating_mild_to_moderate_atopic_dermatitis_in_people_2_years_and_older_(terminated_appraisal).pdf,,Chronic,Drug
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Rejected,2021-04-28,Pembrolizumab_for_treating_locally_advanced_or_metastatic_urothelial_carcinoma_after_platinum-containing_chemotherapy.pdf,,Cancer,Drug
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia,Conditional,2021-04-28,Bempedoic_acid_with_ezetimibe_for_treating_primary_hypercholesterolaemia_or_mixed_dyslipidaemia.pdf,2020-03,"Cardiovascular, Chronic",Drug
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma,Conditional,2021-04-28,Carfilzomib_with_dexamethasone_and_lenalidomide_for_previously_treated_multiple_myeloma.pdf,2020-01,Cancer,Drug
Avelumab for treating metastatic Merkel cell carcinoma,Conditional,2018-04-11,Avelumab_for_treating_metastatic_Merkel_cell_carcinoma.pdf,2017-08,"Cancer, Rare Disease (Orphan Drugs)",Drug
Acalabrutinib for treating chronic lymphocytic leukaemia,Conditional,2021-04-21,Acalabrutinib_for_treating_chronic_lymphocytic_leukaemia.pdf,2020-08,"Cancer, Chronic",Drug
Avelumab for untreated metastatic Merkel cell carcinoma,Conditional,2021-04-21,Avelumab_for_untreated_metastatic_Merkel_cell_carcinoma.pdf,,Cancer,Drug
Anakinra for treating Still’s disease,Approved,2021-03-31,Anakinra_for_treating_Still’s_disease.pdf,2019-10,"Rare Disease (Orphan Drugs), Musculoskeletal diseases",Drug
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal),Rejected,2021-03-31,Blinatumomab_for_previously_treated_Philadelphia-chromosome-positive_acute_lymphoblastic_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
"Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Conditional,2021-03-31,"Ribociclib_with_fulvestrant_for_treating_hormone_receptor-positive,_HER2-negative_advanced_breast_cancer_after_endocrine_therapy.pdf",2020-09,Cancer,Drug
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,Conditional,2021-03-17,Nivolumab_for_adjuvant_treatment_of_completely_resected_melanoma_with_lymph_node_involvement_or_metastatic_disease.pdf,,Cancer,Drug
Erenumab for preventing migraine,Conditional,2021-03-10,Erenumab_for_preventing_migraine.pdf,2018-09,Nervous System,Drug
"Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer",Conditional,2021-03-10,"Pembrolizumab_with_pemetrexed_and_platinum_chemotherapy_for_untreated,_metastatic,_non-squamous_non-small-cell_lung_cancer.pdf",,Cancer,Drug
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,Conditional,2021-03-03,Lenalidomide_maintenance_treatment_after_an_autologous_stem_cell_transplant_for_newly_diagnosed_multiple_myeloma.pdf,2020-02,Cancer,Drug
Baricitinib for treating moderate to severe atopic dermatitis,Conditional,2021-03-03,Baricitinib_for_treating_moderate_to_severe_atopic_dermatitis.pdf,2020-06,Chronic,Drug
Filgotinib for treating moderate to severe rheumatoid arthritis,Conditional,2021-02-24,Filgotinib_for_treating_moderate_to_severe_rheumatoid_arthritis.pdf,,Musculoskeletal diseases,Drug
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma,Approved,2021-02-24,Brexucabtagene_autoleucel_for_treating_relapsed_or_refractory_mantle_cell_lymphoma.pdf,2020-04,Cancer,Drug
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2021-02-24,Omalizumab_for_treating_chronic_rhinosinusitis_with_nasal_polyps_(terminated_appraisal).pdf,,Chronic,Drug
Dapagliflozin for treating chronic heart failure with reduced ejection fraction,Conditional,2021-02-24,Dapagliflozin_for_treating_chronic_heart_failure_with_reduced_ejection_fraction.pdf,2020-05,"Cardiovascular, Chronic",Drug
"Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",Conditional,2021-02-17,"Niraparib_for_maintenance_treatment_of_advanced_ovarian,_fallopian_tube_and_peritoneal_cancer_after_response_to_first-line_platinum-based_chemotherapy.pdf",2020-05,"Cancer, Obstetrics/Gynaecology",Drug
"Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)",Rejected,2021-02-17,"Pembrolizumab_for_untreated_PD-L1-positive,_locally_advanced_or_metastatic_urothelial_cancer_when_cisplatin_is_unsuitable_(terminated_appraisal).pdf",,Cancer,Drug
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal),Rejected,2021-02-17,Vernakalant_for_the_rapid_conversion_of_recent_onset_atrial_fibrillation_to_sinus_rhythm_(terminated_appraisal).pdf,,Cardiovascular,Drug
Trabectedin for the treatment of advanced soft tissue sarcoma,Approved,2010-02-24,Trabectedin_for_the_treatment_of_advanced_soft_tissue_sarcoma.pdf,,Cancer,Drug
Mepolizumab for treating severe eosinophilic asthma,Conditional,2021-02-03,Mepolizumab_for_treating_severe_eosinophilic_asthma.pdf,,Chronic,Drug
Brolucizumab for treating wet age-related macular degeneration,Conditional,2021-02-03,Brolucizumab_for_treating_wet_age-related_macular_degeneration.pdf,2019-10,Nervous System,Drug
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,Conditional,2021-01-27,Brigatinib_for_ALK-positive_advanced_non-small-cell_lung_cancer_that_has_not_been_previously_treated_with_an_ALK_inhibitor.pdf,2020-05,Cancer,Drug
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer,Conditional,2021-01-06,Encorafenib_plus_cetuximab_for_previously_treated_BRAF_V600E_mutation-positive_metastatic_colorectal_cancer.pdf,2019-08,Cancer,Drug
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma,Conditional,2020-12-16,Atezolizumab_with_bevacizumab_for_treating_advanced_or_unresectable_hepatocellular_carcinoma.pdf,2020-04,Cancer,Drug
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura,Conditional,2020-12-16,Caplacizumab_with_plasma_exchange_and_immunosuppression_for_treating_acute_acquired_thrombotic_thrombocytopenic_purpura.pdf,2019-10,Rare Disease (Orphan Drugs),Drug
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia,Conditional,2020-12-09,Venetoclax_with_obinutuzumab_for_untreated_chronic_lymphocytic_leukaemia.pdf,2019-10,"Cancer, Chronic",Drug
Liraglutide for managing overweight and obesity,Conditional,2020-12-09,Liraglutide_for_managing_overweight_and_obesity.pdf,,Chronic,Drug
Upadacitinib for treating severe rheumatoid arthritis,Conditional,2020-12-09,Upadacitinib_for_treating_severe_rheumatoid_arthritis.pdf,2019-07,Musculoskeletal diseases,Drug
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer,Conditional,2020-11-25,Darolutamide_with_androgen_deprivation_therapy_for_treating_hormone-relapsed_non-metastatic_prostate_cancer.pdf,,Cancer,Drug
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,Conditional,2020-11-25,Pembrolizumab_for_untreated_metastatic_or_unresectable_recurrent_head_and_neck_squamous_cell_carcinoma.pdf,2019-06,Cancer,Drug
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal),Rejected,2020-11-25,Durvalumab_in_combination_for_untreated_extensive-stage_small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Drug-eluting stents for the treatment of coronary artery disease,Conditional,2008-07-23,Drug-eluting_stents_for_the_treatment_of_coronary_artery_disease.pdf,,"Cardiovascular, Chronic",Medical Device
Guidance on the use of coronary artery stents,Rejected,2003-10-22,Guidance_on_the_use_of_coronary_artery_stents.pdf,,Cardiovascular,Medical Device
Siponimod for treating secondary progressive multiple sclerosis,Conditional,2020-11-18,Siponimod_for_treating_secondary_progressive_multiple_sclerosis.pdf,2019-09,Nervous System,Drug
Carfilzomib for previously treated multiple myeloma,Conditional,2020-11-18,Carfilzomib_for_previously_treated_multiple_myeloma.pdf,,Cancer,Drug
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma,Conditional,2020-11-18,Isatuximab_with_pomalidomide_and_dexamethasone_for_treating_relapsed_and_refractory_multiple_myeloma.pdf,2020-03,"Cancer, Chronic",Drug
Galcanezumab for preventing migraine,Conditional,2020-11-18,Galcanezumab_for_preventing_migraine.pdf,2020-02,Nervous System,Drug
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy,Conditional,2020-10-21,Nivolumab_for_advanced_squamous_non-small-cell_lung_cancer_after_chemotherapy.pdf,2015-08,Cancer,Drug
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer,Conditional,2020-10-14,Osimertinib_for_treating_EGFR_T790M_mutation-positive_advanced_non-small-cell_lung_cancer.pdf,2019-06,Cancer,Drug
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer,Conditional,2020-10-14,Osimertinib_for_untreated_EGFR_mutation-positive_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma,Rejected,2020-09-30,Pembrolizumab_with_axitinib_for_untreated_advanced_renal_cell_carcinoma.pdf,,Cancer,Drug
Naldemedine for treating opioid-induced constipation,Approved,2020-09-30,Naldemedine_for_treating_opioid-induced_constipation.pdf,2019-06,Nervous System,Drug
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma,Conditional,2020-09-23,Polatuzumab_vedotin_with_rituximab_and_bendamustine_for_treating_relapsed_or_refractory_diffuse_large_B-cell_lymphoma.pdf,2019-07,Cancer,Drug
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal),Rejected,2020-09-09,Dupilumab_for_treating_chronic_rhinosinusitis_with_nasal_polyps_(terminated_appraisal).pdf,,Chronic,Drug
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal),Rejected,2020-09-02,Glasdegib_with_chemotherapy_for_untreated_acute_myeloid_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal),Rejected,2020-09-02,Eculizumab_for_treating_relapsing_neuromyelitis_optica_(terminated_appraisal).pdf,,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Avelumab with axitinib for untreated advanced renal cell carcinoma,Conditional,2020-09-02,Avelumab_with_axitinib_for_untreated_advanced_renal_cell_carcinoma.pdf,2019-07,Cancer,Drug
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma,Approved,2020-08-12,Brentuximab_vedotin_in_combination_for_untreated_systemic_anaplastic_large_cell_lymphoma.pdf,2019-12,Cancer,Drug
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia,Conditional,2020-08-12,Gilteritinib_for_treating_relapsed_or_refractory_acute_myeloid_leukaemia.pdf,2019-06,Cancer,Drug
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer,Conditional,2020-08-12,Entrectinib_for_treating_ROS1-positive_advanced_non-small-cell_lung_cancer.pdf,2019-06,Cancer,Drug
Entrectinib for treating NTRK fusion-positive solid tumours,Approved,2020-08-12,Entrectinib_for_treating_NTRK_fusion-positive_solid_tumours.pdf,2019-05,"Cancer, Rare Disease (Orphan Drugs)",Drug
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant,Approved,2020-08-05,Treosulfan_with_fludarabine_for_malignant_disease_before_allogeneic_stem_cell_transplant.pdf,2019-05,Cancer,Drug
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer,Conditional,2020-07-01,Atezolizumab_with_carboplatin_and_etoposide_for_untreated_extensive-stage_small-cell_lung_cancer.pdf,2019-02,Cancer,Drug
"Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",Conditional,2020-07-01,"Atezolizumab_with_nab-paclitaxel_for_untreated_PD-L1-positive,_locally_advanced_or_metastatic,_triple-negative_breast_cancer.pdf",2019-03,Cancer,Drug
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal),Rejected,2020-06-30,Daratumumab_with_lenalidomide_and_dexamethasone_for_untreated_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal),Rejected,2020-06-30,Ramucirumab_with_erlotinib_for_untreated_EGFR-positive_metastatic_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Eculizumab for treating refractory myasthenia gravis (terminated appraisal),Rejected,2020-06-30,Eculizumab_for_treating_refractory_myasthenia_gravis_(terminated_appraisal).pdf,,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Ranibizumab for treating diabetic retinopathy (terminated appraisal),Rejected,2020-06-30,Ranibizumab_for_treating_diabetic_retinopathy_(terminated_appraisal).pdf,,Chronic,Drug
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure,Approved,2020-06-24,Avatrombopag_for_treating_thrombocytopenia_in_people_with_chronic_liver_disease_needing_a_planned_invasive_procedure.pdf,,Chronic,Drug
Ustekinumab for treating moderately to severely active ulcerative colitis,Conditional,2020-06-17,Ustekinumab_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,,Chronic,Drug
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer,Conditional,2020-06-10,Trastuzumab_emtansine_for_adjuvant_treatment_of_HER2-positive_early_breast_cancer.pdf,2019-09,Cancer,Drug
Larotrectinib for treating NTRK fusion-positive solid tumours,Approved,2020-05-27,Larotrectinib_for_treating_NTRK_fusion-positive_solid_tumours.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer,Approved,2020-05-13,Lorlatinib_for_previously_treated_ALK-positive_advanced_non-small-cell_lung_cancer.pdf,2019-07,Cancer,Drug
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab,Conditional,2020-05-13,Obinutuzumab_with_bendamustine_for_treating_follicular_lymphoma_after_rituximab.pdf,2019-11,Cancer,Drug
Lenalidomide with rituximab for previously treated follicular lymphoma,Approved,2020-04-07,Lenalidomide_with_rituximab_for_previously_treated_follicular_lymphoma.pdf,,Cancer,Drug
Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal),Rejected,2020-03-04,Recombinant_human_parathyroid_hormone_for_treating_hypoparathyroidism_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis,Approved,2020-02-19,Peginterferon_beta-1a_for_treating_relapsing–remitting_multiple_sclerosis.pdf,2019-06,Nervous System,Drug
Patiromer for treating hyperkalaemia,Conditional,2020-02-13,Patiromer_for_treating_hyperkalaemia.pdf,2018-09,Cardiovascular,Drug
Sotagliflozin with insulin for treating type 1 diabetes,Conditional,2020-02-12,Sotagliflozin_with_insulin_for_treating_type_1_diabetes.pdf,2019-02,Chronic,Drug
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal),Rejected,2020-01-15,Atezolizumab_with_carboplatin_and_nab-paclitaxel_for_untreated_advanced_non-squamous_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure,Approved,2020-01-08,Lusutrombopag_for_treating_thrombocytopenia_in_people_with_chronic_liver_disease_needing_a_planned_invasive_procedure.pdf,2019-04,Chronic,Drug
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome,Conditional,2019-12-18,Cannabidiol_with_clobazam_for_treating_seizures_associated_with_Dravet_syndrome.pdf,2019-04,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome,Conditional,2019-12-18,Cannabidiol_with_clobazam_for_treating_seizures_associated_with_Lennox–Gastaut_syndrome.pdf,2019-05,"Chronic, Nervous System, Rare Disease (Orphan Drugs)",Drug
"Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",Conditional,2019-11-20,"Neratinib_for_extended_adjuvant_treatment_of_hormone_receptor-positive,_HER2-positive_early_stage_breast_cancer_after_adjuvant_trastuzumab.pdf",,Cancer,Drug
Pentosan polysulfate sodium for treating bladder pain syndrome,Conditional,2019-11-13,Pentosan_polysulfate_sodium_for_treating_bladder_pain_syndrome.pdf,,Urinary-Track Diseases,Drug
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal),Rejected,2019-10-30,Ibrutinib_with_rituximab_for_treating_Waldenstrom’s_macroglobulinaemia_(terminated_appraisal).pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal),Rejected,2019-10-30,Ramucirumab_for_treating_unresectable_hepatocellular_carcinoma_after_sorafenib_(terminated_appraisal).pdf,,Cancer,Drug
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease,Approved,2019-10-17,Rivaroxaban_for_preventing_atherothrombotic_events_in_people_with_coronary_or_peripheral_artery_disease.pdf,2018-12,Cardiovascular,Drug
Lanadelumab for preventing recurrent attacks of hereditary angioedema,Conditional,2019-10-16,Lanadelumab_for_preventing_recurrent_attacks_of_hereditary_angioedema.pdf,,Rare Disease (Orphan Drugs),Drug
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea,Conditional,2019-10-09,Xeomin_(botulinum_neurotoxin_type_A)_for_treating_chronic_sialorrhoea.pdf,2019-02,"Chronic, Nervous System",Drug
Idelalisib for treating refractory follicular lymphoma,Rejected,2019-10-02,Idelalisib_for_treating_refractory_follicular_lymphoma.pdf,2018-06,Cancer,Drug
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal),Rejected,2019-09-25,Lenalidomide_with_bortezomib_and_dexamethasone_for_untreated_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2019-09-25,Pomalidomide_with_bortezomib_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Benralizumab for treating severe eosinophilic asthma,Conditional,2019-03-06,Benralizumab_for_treating_severe_eosinophilic_asthma.pdf,2018-01,Chronic,Drug
Risankizumab for treating moderate to severe plaque psoriasis,Conditional,2019-08-21,Risankizumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2018-12,Chronic,Drug
Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal),Rejected,2019-08-14,Brentuximab_vedotin_for_untreated_advanced_Hodgkin_lymphoma_(terminated_appraisal).pdf,,Cancer,Drug
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer,Conditional,2019-08-14,Dacomitinib_for_untreated_EGFR_mutation-positive_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis,Conditional,2019-07-31,Fluocinolone_acetonide_intravitreal_implant_for_treating_recurrent_non-infectious_uveitis.pdf,2018-11,Chronic,Medical Device
Letermovir for preventing cytomegalovirus disease after a stem cell transplant,Conditional,2019-07-31,Letermovir_for_preventing_cytomegalovirus_disease_after_a_stem_cell_transplant.pdf,2018-03,Rare Disease (Orphan Drugs),Drug
Nusinersen for treating spinal muscular atrophy,Conditional,2019-07-24,Nusinersen_for_treating_spinal_muscular_atrophy.pdf,2018-03,"Nervous System, Rare Disease (Orphan Drugs)",Drug
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity,Conditional,2019-07-24,Blinatumomab_for_treating_acute_lymphoblastic_leukaemia_in_remission_with_minimal_residual_disease_activity.pdf,,Cancer,Drug
Bisphosphonates for treating osteoporosis,Rejected,2017-08-09,Bisphosphonates_for_treating_osteoporosis.pdf,,Musculoskeletal diseases,Drug
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,Conditional,2014-09-24,Lenalidomide_for_treating_myelodysplastic_syndromes_associated_with_an_isolated_deletion_5q_cytogenetic_abnormality.pdf,,"Chronic, Cancer",Drug
Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies,Conditional,2009-06-18,Lenalidomide_for_the_treatment_of_multiple_myeloma_in_people_who_have_received_at_least_2_prior_therapies.pdf,,Cancer,Drug
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib,Conditional,2019-06-26,Lenalidomide_plus_dexamethasone_for_multiple_myeloma_after_1_treatment_with_bortezomib.pdf,,Cancer,Drug
Lenalidomide plus dexamethasone for previously untreated multiple myeloma,Conditional,2019-06-26,Lenalidomide_plus_dexamethasone_for_previously_untreated_multiple_myeloma.pdf,2017-10,Cancer,Drug
Ocrelizumab for treating primary progressive multiple sclerosis,Conditional,2019-06-12,Ocrelizumab_for_treating_primary_progressive_multiple_sclerosis.pdf,,Nervous System,Drug
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes,Conditional,2019-06-05,Ertugliflozin_with_metformin_and_a_dipeptidyl_peptidase-4_inhibitor_for_treating_type_2_diabetes.pdf,,Chronic,Drug
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer,Approved,2019-06-05,Atezolizumab_in_combination_for_treating_metastatic_non-squamous_non-small-cell_lung_cancer.pdf,2018-09,Cancer,Drug
Enzalutamide for hormone-relapsed non-metastatic prostate cancer,Rejected,2019-05-15,Enzalutamide_for_hormone-relapsed_non-metastatic_prostate_cancer.pdf,2018-09,Cancer,Drug
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma,Conditional,2019-04-24,Brentuximab_vedotin_for_treating_CD30-positive_cutaneous_T-cell_lymphoma.pdf,2018-06,Cancer,Drug
Certolizumab pegol for treating moderate to severe plaque psoriasis,Conditional,2019-04-17,Certolizumab_pegol_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2018-08,Chronic,Drug
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal),Rejected,2019-04-17,Bosutinib_for_untreated_chronic_myeloid_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
Tildrakizumab for treating moderate to severe plaque psoriasis,Conditional,2019-04-17,Tildrakizumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2018-08,Chronic,Drug
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes,Conditional,2019-03-27,Ertugliflozin_as_monotherapy_or_with_metformin_for_treating_type_2_diabetes.pdf,,Chronic,Drug
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib,Conditional,2019-03-20,Brigatinib_for_treating_ALK-positive_advanced_non-small-cell_lung_cancer_after_crizotinib.pdf,,Cancer,Drug
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal),Rejected,2019-03-20,Pembrolizumab_for_treating_recurrent_or_metastatic_squamous_cell_carcinoma_of_the_head_and_neck_after_platinum-based_chemotherapy_(terminated_appraisal).pdf,,Cancer,Drug
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer,Conditional,2019-03-20,Pertuzumab_for_adjuvant_treatment_of_HER2-positive_early_stage_breast_cancer.pdf,2018-02,Cancer,Drug
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal),Rejected,2019-03-13,Abatacept_for_treating_psoriatic_arthritis_after_DMARDs_(terminated_appraisal).pdf,,Musculoskeletal diseases,Drug
Cochlear implants for children and adults with severe to profound deafness,Rejected,2019-03-07,Cochlear_implants_for_children_and_adults_with_severe_to_profound_deafness.pdf,,Nervous System,Medical Device
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia,Conditional,2019-02-27,Venetoclax_with_rituximab_for_previously_treated_chronic_lymphocytic_leukaemia.pdf,2018-06,"Chronic, Cancer",Drug
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma,Conditional,2019-02-27,Encorafenib_with_binimetinib_for_unresectable_or_metastatic_BRAF_V600_mutation-positive_melanoma.pdf,2018-09,Cancer,Drug
"Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2019-02-27,"Abemaciclib_with_an_aromatase_inhibitor_for_previously_untreated,_hormone_receptor-positive,_HER2-negative,_locally_advanced_or_metastatic_breast_cancer.pdf",2018-06,Cancer,Drug
"Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)",Rejected,2019-02-20,"Bevacizumab_with_carboplatin,_gemcitabine_and_paclitaxel_for_treating_the_first_recurrence_of_platinum-sensitive_advanced_ovarian_cancer_(terminated_appraisal).pdf",,"Cancer, Obstetrics/Gynaecology",Drug
Regorafenib for previously treated advanced hepatocellular carcinoma,Conditional,2019-01-09,Regorafenib_for_previously_treated_advanced_hepatocellular_carcinoma.pdf,,Cancer,Drug
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease,Rejected,2019-01-09,Darvadstrocel_for_treating_complex_perianal_fistulas_in_Crohn’s_disease.pdf,2018-04,Chronic,Drug
Lenvatinib for untreated advanced hepatocellular carcinoma,Conditional,2018-12-19,Lenvatinib_for_untreated_advanced_hepatocellular_carcinoma.pdf,2018-02,Cancer,Drug
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia,Conditional,2018-12-19,Liposomal_cytarabine–daunorubicin_for_untreated_acute_myeloid_leukaemia.pdf,2018-08,Cancer,Drug
Vandetanib for treating medullary thyroid cancer,Rejected,2018-12-12,Vandetanib_for_treating_medullary_thyroid_cancer.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Decitabine for untreated acute myeloid leukaemia (terminated appraisal),Rejected,2018-12-05,Decitabine_for_untreated_acute_myeloid_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal),Rejected,2018-12-05,Denosumab_for_preventing_skeletal-related_events_in_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Tofacitinib for moderately to severely active ulcerative colitis,Conditional,2018-11-28,Tofacitinib_for_moderately_to_severely_active_ulcerative_colitis.pdf,2018-05,Chronic,Drug
Padeliporfin for untreated localised prostate cancer,Rejected,2018-11-21,Padeliporfin_for_untreated_localised_prostate_cancer.pdf,2018-02,Cancer,Drug
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia,Conditional,2018-11-14,Gemtuzumab_ozogamicin_for_untreated_acute_myeloid_leukaemia.pdf,2017-12,Cancer,Drug
Eltrombopag for treating chronic immune thrombocytopenia,Conditional,2013-07-24,Eltrombopag_for_treating_chronic_immune_thrombocytopenia.pdf,,Chronic,Drug
Romiplostim for the treatment of chronic immune thrombocytopenia,Conditional,2011-04-27,Romiplostim_for_the_treatment_of_chronic_immune_thrombocytopenia.pdf,,"Chronic, Rare Disease (Orphan Drugs)",Drug
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma,Conditional,2018-10-17,Dabrafenib_with_trametinib_for_adjuvant_treatment_of_resected_BRAF_V600_mutation-positive_melanoma.pdf,2018-04,Cancer,Drug
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2018-10-03,Tofacitinib_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,,"Chronic, Musculoskeletal diseases",Drug
Cabozantinib for untreated advanced renal cell carcinoma,Conditional,2018-10-03,Cabozantinib_for_untreated_advanced_renal_cell_carcinoma.pdf,2018-01,Cancer,Drug
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia,Conditional,2018-09-19,Inotuzumab_ozogamicin_for_treating_relapsed_or_refractory_B-cell_acute_lymphoblastic_leukaemia.pdf,,Cancer,Drug
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours,Conditional,2018-08-29,Lutetium_(177Lu)_oxodotreotide_for_treating_unresectable_or_metastatic_neuroendocrine_tumours.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Dinutuximab beta for treating neuroblastoma,Conditional,2018-08-22,Dinutuximab_beta_for_treating_neuroblastoma.pdf,2017-06,"Cancer, Rare Disease (Orphan Drugs)",Drug
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine,Conditional,2018-08-08,Lenvatinib_and_sorafenib_for_treating_differentiated_thyroid_cancer_after_radioactive_iodine.pdf,,Cancer,Drug
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer,Conditional,2018-08-08,Alectinib_for_untreated_ALK-positive_advanced_non-small-cell_lung_cancer.pdf,2017-10,Cancer,Drug
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2018-08-08,Ixekizumab_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,,"Chronic, Musculoskeletal diseases",Drug
Dupilumab for treating moderate to severe atopic dermatitis,Conditional,2018-08-01,Dupilumab_for_treating_moderate_to_severe_atopic_dermatitis.pdf,2018-03,Chronic,Drug
Ocrelizumab for treating relapsing–remitting multiple sclerosis,Conditional,2018-07-25,Ocrelizumab_for_treating_relapsing–remitting_multiple_sclerosis.pdf,2017-11,Nervous System,Drug
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer,Conditional,2018-07-18,Pembrolizumab_for_untreated_PD-L1-positive_metastatic_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy,Rejected,2018-07-04,Nivolumab_for_treating_locally_advanced_unresectable_or_metastatic_urothelial_cancer_after_platinum-containing_chemotherapy.pdf,2017-06,"Cancer, Urinary-Track Diseases",Drug
Beta interferons and glatiramer acetate for treating multiple sclerosis,Rejected,2018-06-27,Beta_interferons_and_glatiramer_acetate_for_treating_multiple_sclerosis.pdf,,"Nervous System, Chronic",Drug
"Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease",Approved,2011-03-23,"Donepezil,_galantamine,_rivastigmine_and_memantine_for_the_treatment_of_Alzheimer's_disease.pdf",,"Chronic, Nervous System",Drug
502 Bad Gateway,Rejected,2018-06-13,502_Bad_Gateway.pdf,2017-10,NULL,
Midostaurin for untreated acute myeloid leukaemia,Conditional,2018-06-13,Midostaurin_for_untreated_acute_myeloid_leukaemia.pdf,,Cancer,Drug
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma,Conditional,2018-06-13,Brentuximab_vedotin_for_treating_CD30-positive_Hodgkin_lymphoma.pdf,,Cancer,Drug
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Conditional,2018-06-13,Atezolizumab_for_treating_locally_advanced_or_metastatic_urothelial_carcinoma_after_platinum-containing_chemotherapy.pdf,,Cancer,Drug
Arsenic trioxide for treating acute promyelocytic leukaemia,Approved,2018-06-13,Arsenic_trioxide_for_treating_acute_promyelocytic_leukaemia.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy,Conditional,2018-05-16,Atezolizumab_for_treating_locally_advanced_or_metastatic_non-small-cell_lung_cancer_after_chemotherapy.pdf,2017-02,Cancer,Drug
Tocilizumab for treating giant cell arteritis,Conditional,2018-04-18,Tocilizumab_for_treating_giant_cell_arteritis.pdf,2017-08,Cardiovascular,Drug
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen,Rejected,2018-03-28,Eribulin_for_treating_locally_advanced_or_metastatic_breast_cancer_after_1_chemotherapy_regimen.pdf,2016-04,Cancer,Drug
Cabozantinib for treating medullary thyroid cancer,Conditional,2018-03-28,Cabozantinib_for_treating_medullary_thyroid_cancer.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Brodalumab for treating moderate to severe plaque psoriasis,Conditional,2018-03-21,Brodalumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2017-09,Chronic,Drug
Tivozanib for treating advanced renal cell carcinoma,Conditional,2018-03-21,Tivozanib_for_treating_advanced_renal_cell_carcinoma.pdf,2017-05,Cancer,Drug
Obinutuzumab for untreated advanced follicular lymphoma,Conditional,2018-03-21,Obinutuzumab_for_untreated_advanced_follicular_lymphoma.pdf,2017-05,Cancer,Drug
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee,Conditional,2018-03-07,Autologous_chondrocyte_implantation_using_chondrosphere_for_treating_symptomatic_articular_cartilage_defects_of_the_knee.pdf,2017-12,Musculoskeletal diseases,Other treatment
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer,Conditional,2018-03-07,Pertuzumab_with_trastuzumab_and_docetaxel_for_treating_HER2-positive_breast_cancer.pdf,,Cancer,Drug
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C,Conditional,2018-02-21,Sofosbuvir–velpatasvir–voxilaprevir_for_treating_chronic_hepatitis_C.pdf,2017-08,Chronic,Drug
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women,Rejected,2008-10-27,Raloxifene_for_the_primary_prevention_of_osteoporotic_fragility_fractures_in_postmenopausal_women.pdf,,Musculoskeletal diseases,Drug
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women,Approved,2008-10-27,Raloxifene_and_teriparatide_for_the_secondary_prevention_of_osteoporotic_fragility_fractures_in_postmenopausal_women.pdf,,Musculoskeletal diseases,Drug
Pirfenidone for treating idiopathic pulmonary fibrosis,Conditional,2018-02-06,Pirfenidone_for_treating_idiopathic_pulmonary_fibrosis.pdf,2016-02,Rare Disease (Orphan Drugs),Drug
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer,Rejected,2018-01-31,Intrabeam_radiotherapy_system_for_adjuvant_treatment_of_early_breast_cancer.pdf,,Cancer,Medical Device
Ibrutinib for treating relapsed or refractory mantle cell lymphoma,Conditional,2018-01-31,Ibrutinib_for_treating_relapsed_or_refractory_mantle_cell_lymphoma.pdf,2016-04,Cancer,Drug
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,Rejected,2018-01-31,Fulvestrant_for_untreated_locally_advanced_or_metastatic_oestrogen-receptor_positive_breast_cancer.pdf,2017-03,Cancer,Drug
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma,Conditional,2018-01-24,Lenvatinib_with_everolimus_for_previously_treated_advanced_renal_cell_carcinoma.pdf,2017-03,Cancer,Drug
Glecaprevir–pibrentasvir for treating chronic hepatitis C,Conditional,2018-01-24,Glecaprevir–pibrentasvir_for_treating_chronic_hepatitis_C.pdf,2017-07,Chronic,Drug
Ceritinib for untreated ALK-positive non-small-cell lung cancer,Conditional,2018-01-24,Ceritinib_for_untreated_ALK-positive_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Golimumab for treating non-radiographic axial spondyloarthritis,Conditional,2018-01-10,Golimumab_for_treating_non-radiographic_axial_spondyloarthritis.pdf,,Musculoskeletal diseases,Drug
"Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2017-12-20,"Palbociclib_with_an_aromatase_inhibitor_for_previously_untreated,_hormone_receptor-positive,_HER2-negative,_locally_advanced_or_metastatic_breast_cancer.pdf",,Cancer,Drug
"Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Conditional,2017-12-20,"Ribociclib_with_an_aromatase_inhibitor_for_previously_untreated,_hormone_receptor-positive,_HER2-negative,_locally_advanced_or_metastatic_breast_cancer.pdf",,Cancer,Drug
Naltrexone–bupropion for managing overweight and obesity,Rejected,2017-12-12,Naltrexone–bupropion_for_managing_overweight_and_obesity.pdf,,Chronic,Drug
Vismodegib for treating basal cell carcinoma,Rejected,2017-11-22,Vismodegib_for_treating_basal_cell_carcinoma.pdf,2017-03,Cancer,Drug
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane,Conditional,2017-07-19,Trastuzumab_emtansine_for_treating_HER2-positive_advanced_breast_cancer_after_trastuzumab_and_a_taxane.pdf,,Cancer,Drug
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours,Conditional,2017-11-15,Regorafenib_for_previously_treated_unresectable_or_metastatic_gastrointestinal_stromal_tumours.pdf,,Cancer,Drug
Sarilumab for moderate to severe rheumatoid arthritis,Conditional,2017-11-01,Sarilumab_for_moderate_to_severe_rheumatoid_arthritis.pdf,2017-05,Musculoskeletal diseases,Drug
Aflibercept for treating choroidal neovascularisation,Conditional,2017-11-01,Aflibercept_for_treating_choroidal_neovascularisation.pdf,2017-05,Cancer,Drug
Tofacitinib for moderate to severe rheumatoid arthritis,Conditional,2017-10-11,Tofacitinib_for_moderate_to_severe_rheumatoid_arthritis.pdf,2011-04,Musculoskeletal diseases,Drug
Immunosuppressive therapy for kidney transplant in adults,Rejected,2017-10-11,Immunosuppressive_therapy_for_kidney_transplant_in_adults.pdf,,Urinary-Track Diseases,Drug
Immunosuppressive therapy for kidney transplant in children and young people,Rejected,2017-10-11,Immunosuppressive_therapy_for_kidney_transplant_in_children_and_young_people.pdf,,Urinary-Track Diseases,Drug
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee,Conditional,2017-10-04,Autologous_chondrocyte_implantation_for_treating_symptomatic_articular_cartilage_defects_of_the_knee.pdf,,Musculoskeletal diseases,Other treatment
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma,Conditional,2017-10-04,Brentuximab_vedotin_for_treating_relapsed_or_refractory_systemic_anaplastic_large_cell_lymphoma.pdf,,Cancer,Drug
Reslizumab for treating severe eosinophilic asthma,Conditional,2017-10-04,Reslizumab_for_treating_severe_eosinophilic_asthma.pdf,,Chronic,Drug
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer,Approved,2017-03-29,Cetuximab_and_panitumumab_for_previously_untreated_metastatic_colorectal_cancer.pdf,,Cancer,Drug
Pembrolizumab for advanced melanoma not previously treated with ipilimumab,Approved,2015-11-25,Pembrolizumab_for_advanced_melanoma_not_previously_treated_with_ipilimumab.pdf,,Cancer,Drug
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy,Conditional,2017-01-11,Pembrolizumab_for_treating_PD-L1-positive_non-small-cell_lung_cancer_after_chemotherapy.pdf,,Cancer,Drug
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab,Approved,2015-10-07,Pembrolizumab_for_treating_advanced_melanoma_after_disease_progression_with_ipilimumab.pdf,,Cancer,Drug
Sorafenib for treating advanced hepatocellular carcinoma,Conditional,2017-09-06,Sorafenib_for_treating_advanced_hepatocellular_carcinoma.pdf,,Cancer,Drug
Dimethyl fumarate for treating moderate to severe plaque psoriasis,Conditional,2017-09-06,Dimethyl_fumarate_for_treating_moderate_to_severe_plaque_psoriasis.pdf,2017-05,Chronic,Drug
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer,Conditional,2017-09-06,Paclitaxel_as_albumin-bound_nanoparticles_with_gemcitabine_for_untreated_metastatic_pancreatic_cancer.pdf,,Cancer,Drug
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck,Approved,2017-08-31,Cetuximab_for_treating_recurrent_or_metastatic_squamous_cell_cancer_of_the_head_and_neck.pdf,,Cancer,Drug
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal),Rejected,2017-08-23,Methylnaltrexone_bromide_for_treating_opioid-induced_constipation_(terminated_appraisal).pdf,,Chronic,Drug
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal),Rejected,2017-08-23,Idelalisib_with_ofatumumab_for_treating_chronic_lymphocytic_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
Holoclar for treating limbal stem cell deficiency after eye burns,Conditional,2017-08-16,Holoclar_for_treating_limbal_stem_cell_deficiency_after_eye_burns.pdf,,Rare Disease (Orphan Drugs),Drug
Pemetrexed for the maintenance treatment of non-small-cell lung cancer,Approved,2010-06-23,Pemetrexed_for_the_maintenance_treatment_of_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Cabozantinib for previously treated advanced renal cell carcinoma,Conditional,2017-08-09,Cabozantinib_for_previously_treated_advanced_renal_cell_carcinoma.pdf,2016-09,Cancer,Drug
Baricitinib for moderate to severe rheumatoid arthritis,Conditional,2017-08-09,Baricitinib_for_moderate_to_severe_rheumatoid_arthritis.pdf,,Musculoskeletal diseases,Drug
Adalimumab and dexamethasone for treating non-infectious uveitis,Conditional,2017-07-26,Adalimumab_and_dexamethasone_for_treating_non-infectious_uveitis.pdf,,Chronic,Drug
Roflumilast for treating chronic obstructive pulmonary disease,Conditional,2017-07-26,Roflumilast_for_treating_chronic_obstructive_pulmonary_disease.pdf,,Chronic,Drug
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma,Approved,2017-07-26,Nivolumab_for_treating_relapsed_or_refractory_classical_Hodgkin_lymphoma.pdf,2016-11,Cancer,Drug
"Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people",Conditional,2017-07-12,"Adalimumab,_etanercept_and_ustekinumab_for_treating_plaque_psoriasis_in_children_and_young_people.pdf",2016-09,Chronic,Drug
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment,Approved,2017-07-12,Ustekinumab_for_moderately_to_severely_active_Crohn’s_disease_after_previous_treatment.pdf,,Chronic,Drug
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal),Rejected,2017-07-05,Ibrutinib_for_untreated_chronic_lymphocytic_leukaemia_without_a_17p_deletion_or_TP53_mutation_(terminated_appraisal).pdf,,"Cancer, Chronic",Drug
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal),Rejected,2017-07-05,Bortezomib_for_treating_multiple_myeloma_after_second_or_subsequent_relapse_(terminated_appraisal).pdf,,Cancer,Drug
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal),Rejected,2017-07-05,Daratumumab_with_lenalidomide_and_dexamethasone_for_treating_relapsed_or_refractory_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Etelcalcetide for treating secondary hyperparathyroidism,Conditional,2017-06-28,Etelcalcetide_for_treating_secondary_hyperparathyroidism.pdf,,Chronic,Drug
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease,Approved,2017-06-28,Everolimus_and_sunitinib_for_treating_unresectable_or_metastatic_neuroendocrine_tumours_in_people_with_progressive_disease.pdf,2016-09,Cancer,Drug
Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,Conditional,2017-06-28,Blinatumomab_for_previously_treated_Philadelphia-chromosome-negative_acute_lymphoblastic_leukaemia.pdf,,Cancer,Drug
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia,Conditional,2017-06-28,Ponatinib_for_treating_chronic_myeloid_leukaemia_and_acute_lymphoblastic_leukaemia.pdf,2016-10,Cancer,Drug
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal),Rejected,2017-05-24,Afatinib_for_treating_advanced_squamous_non-small-cell_lung_cancer_after_platinum-based_chemotherapy_(terminated_appraisal).pdf,,Cancer,Drug
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs,Conditional,2017-05-24,Certolizumab_pegol_and_secukinumab_for_treating_active_psoriatic_arthritis_after_inadequate_response_to_DMARDs.pdf,,"Chronic, Musculoskeletal diseases",Drug
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine,Rejected,2017-04-26,Pegylated_liposomal_irinotecan_for_treating_pancreatic_cancer_after_gemcitabine.pdf,,Cancer,Drug
Ixekizumab for treating moderate to severe plaque psoriasis,Conditional,2017-04-26,Ixekizumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,,Chronic,Drug
Obeticholic acid for treating primary biliary cholangitis,Conditional,2017-04-26,Obeticholic_acid_for_treating_primary_biliary_cholangitis.pdf,,"Chronic, Rare Disease (Orphan Drugs)",Drug
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal),Rejected,2017-03-29,Alectinib_for_previously_treated_anaplastic_lymphoma_kinase-positive_advanced_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal),Rejected,2011-12-14,Panitumumab_in_combination_with_chemotherapy_for_the_treatment_of_metastatic_colorectal_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal),Rejected,2017-03-22,Bevacizumab_for_treating_EGFR_mutation-positive_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal),Rejected,2017-03-22,Ibrutinib_with_bendamustine_and_rituximab_for_treating_relapsed_or_refractory_chronic_lymphocytic_leukaemia_after_systemic_therapy_(terminated_appraisal).pdf,,Cancer,Drug
Elotuzumab for previously treated multiple myeloma (terminated appraisal),Rejected,2017-03-22,Elotuzumab_for_previously_treated_multiple_myeloma_(terminated_appraisal).pdf,,Cancer,Drug
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal),Rejected,2017-03-22,Tenofovir_alafenamide_for_treating_chronic_hepatitis_B_(terminated_appraisal).pdf,,Chronic,Drug
Ustekinumab for treating active psoriatic arthritis,Rejected,2015-06-04,Ustekinumab_for_treating_active_psoriatic_arthritis.pdf,,Musculoskeletal diseases,Drug
Ustekinumab for the treatment of adults with moderate to severe psoriasis,Approved,2009-09-23,Ustekinumab_for_the_treatment_of_adults_with_moderate_to_severe_psoriasis.pdf,,Chronic,Drug
Everolimus for advanced renal cell carcinoma after previous treatment,Conditional,2017-02-22,Everolimus_for_advanced_renal_cell_carcinoma_after_previous_treatment.pdf,,Cancer,Drug
Apremilast for treating active psoriatic arthritis,Conditional,2017-02-22,Apremilast_for_treating_active_psoriatic_arthritis.pdf,,Musculoskeletal diseases,Drug
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,Approved,2017-01-25,Ibrutinib_for_previously_treated_chronic_lymphocytic_leukaemia_and_untreated_chronic_lymphocytic_leukaemia_with_17p_deletion_or_TP53_mutation.pdf,2015-10,Cancer,Drug
Sofosbuvir–velpatasvir for treating chronic hepatitis C,Conditional,2017-01-25,Sofosbuvir–velpatasvir_for_treating_chronic_hepatitis_C.pdf,2016-09,Chronic,Drug
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib,Approved,2017-01-11,Pomalidomide_for_multiple_myeloma_previously_treated_with_lenalidomide_and_bortezomib.pdf,,Cancer,Drug
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy,Conditional,2016-12-21,Everolimus_with_exemestane_for_treating_advanced_breast_cancer_after_endocrine_therapy.pdf,,Cancer,Drug
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Conditional,2016-12-21,Crizotinib_for_previously_treated_anaplastic_lymphoma_kinase-positive_advanced_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,Approved,2016-12-21,Eribulin_for_treating_locally_advanced_or_metastatic_breast_cancer_after_2_or_more_chemotherapy_regimens.pdf,2016-04,Cancer,Drug
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer,Conditional,2016-12-21,Pertuzumab_for_the_neoadjuvant_treatment_of_HER2-positive_breast_cancer.pdf,,Cancer,Drug
"Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia",Rejected,2016-12-21,"Dasatinib,_nilotinib_and_high-dose_imatinib_for_treating_imatinib-resistant_or_intolerant_chronic_myeloid_leukaemia.pdf",2016-08,"Cancer, Chronic",Drug
"Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia",Conditional,2016-12-21,"Dasatinib,_nilotinib_and_imatinib_for_untreated_chronic_myeloid_leukaemia.pdf",2016-08,"Chronic, Cancer",Drug
Ticagrelor for preventing atherothrombotic events after myocardial infarction,Approved,2016-12-14,Ticagrelor_for_preventing_atherothrombotic_events_after_myocardial_infarction.pdf,2016-04,Cardiovascular,Drug
Dapagliflozin in combination therapy for treating type 2 diabetes,Rejected,2013-06-26,Dapagliflozin_in_combination_therapy_for_treating_type 2_diabetes.pdf,,Chronic,Drug
Nivolumab for previously treated advanced renal cell carcinoma,Approved,2016-11-23,Nivolumab_for_previously_treated_advanced_renal_cell_carcinoma.pdf,,"Cancer, Urinary-Track Diseases",Drug
Dapagliflozin in triple therapy for treating type 2 diabetes,Approved,2016-11-23,Dapagliflozin_in_triple_therapy_for_treating_type_2_diabetes.pdf,2016-04,Chronic,Drug
Apremilast for treating moderate to severe plaque psoriasis,Conditional,2016-11-23,Apremilast_for_treating_moderate_to_severe_plaque_psoriasis.pdf,,Chronic,Drug
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,Conditional,2016-10-26,Certolizumab_pegol_for_treating_rheumatoid_arthritis_after_inadequate_response_to_a_TNF-alpha_inhibitor.pdf,2016-02,Musculoskeletal diseases,Drug
Elbasvir–grazoprevir for treating chronic hepatitis C,Conditional,2016-10-26,Elbasvir–grazoprevir_for_treating_chronic_hepatitis_C.pdf,,Chronic,Drug
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma,Rejected,2016-10-26,Cobimetinib_in_combination_with_vemurafenib_for_treating_unresectable_or_metastatic_BRAF_V600_mutation-positive_melanoma.pdf,2016-02,Cancer,Drug
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer,Rejected,2016-09-28,Necitumumab_for_untreated_advanced_or_metastatic_squamous_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases,Conditional,2016-09-28,Radium-223_dichloride_for_treating_hormone-relapsed_prostate_cancer_with_bone_metastases.pdf,,Cancer,Drug
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Conditional,2016-09-28,Crizotinib_for_untreated_anaplastic_lymphoma_kinase-positive_advanced_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,Conditional,2016-09-28,Secukinumab_for_active_ankylosing_spondylitis_after_treatment_with_non-steroidal_anti-inflammatory_drugs_or_TNF-alpha_inhibitors.pdf,2016-02,Musculoskeletal diseases,Drug
Pegaspargase for treating acute lymphoblastic leukaemia,Approved,2016-09-28,Pegaspargase_for_treating_acute_lymphoblastic_leukaemia.pdf,,Cancer,Drug
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion,Conditional,2016-09-28,Aflibercept_for_treating_visual_impairment_caused_by_macular_oedema_after_branch_retinal_vein_occlusion.pdf,,Chronic,Drug
Talimogene laherparepvec for treating unresectable metastatic melanoma,Conditional,2016-09-28,Talimogene_laherparepvec_for_treating_unresectable_metastatic_melanoma.pdf,,Cancer,Drug
Bosutinib for previously treated chronic myeloid leukaemia,Approved,2016-08-24,Bosutinib_for_previously_treated_chronic_myeloid_leukaemia.pdf,,Cancer,Drug
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,Approved,2016-08-24,Pemetrexed_maintenance_treatment_for_non-squamous_non-small-cell_lung_cancer_after_pemetrexed_and_cisplatin.pdf,,Cancer,Drug
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer,Rejected,2016-08-24,Ramucirumab_for_previously_treated_locally_advanced_or_metastatic_non-small-cell_lung_cancer.pdf,2015-12,Cancer,Drug
Degarelix for treating advanced hormone-dependent prostate cancer,Conditional,2016-08-24,Degarelix_for_treating_advanced_hormone-dependent_prostate_cancer.pdf,,Cancer,Drug
Trifluridine–tipiracil for previously treated metastatic colorectal cancer,Approved,2016-08-24,Trifluridine–tipiracil_for_previously_treated_metastatic_colorectal_cancer.pdf,2016-02,Cancer,Drug
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel,Rejected,2016-05-25,Cabazitaxel_for_hormone-relapsed_metastatic_prostate_cancer_treated_with_docetaxel.pdf,2015-10,Cancer,Drug
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen,Conditional,2012-06-27,Abiraterone_for_castration-resistant_metastatic_prostate_cancer_previously_treated_with_a_docetaxel-containing_regimen.pdf,,Cancer,Drug
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts,Rejected,2016-07-27,Azacitidine_for_treating_acute_myeloid_leukaemia_with_more_than_30%_bone_marrow_blasts.pdf,,Cancer,Drug
Nivolumab in combination with ipilimumab for treating advanced melanoma,Approved,2016-07-27,Nivolumab_in_combination_with_ipilimumab_for_treating_advanced_melanoma.pdf,,Cancer,Drug
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Approved,2016-04-27,Abiraterone_for_treating_metastatic_hormone-relapsed_prostate_cancer_before_chemotherapy_is_indicated.pdf,,Cancer,Drug
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia,Conditional,2016-06-22,Alirocumab_for_treating_primary_hypercholesterolaemia_and_mixed_dyslipidaemia.pdf,2015-09,"Cardiovascular, Chronic",Drug
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia,Conditional,2016-06-22,Evolocumab_for_treating_primary_hypercholesterolaemia_and_mixed_dyslipidaemia.pdf,,"Cardiovascular, Chronic",Drug
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,Conditional,2016-06-22,Ceritinib_for_previously_treated_anaplastic_lymphoma_kinase_positive_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma,Approved,2016-06-22,Trametinib_in_combination_with_dabrafenib_for_treating_unresectable_or_metastatic_melanoma.pdf,,Cancer,Drug
Adalimumab for treating moderate to severe hidradenitis suppurativa,Conditional,2016-06-22,Adalimumab_for_treating_moderate_to_severe_hidradenitis_suppurativa.pdf,2015-10,Chronic,Drug
"Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes",Rejected,2016-05-25,"Canagliflozin,_dapagliflozin_and_empagliflozin_as_monotherapies_for_treating_type_2_diabetes.pdf",,Chronic,Drug
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction,Approved,2016-04-27,Sacubitril_valsartan_for_treating_symptomatic_chronic_heart_failure_with_reduced_ejection_fraction.pdf,,"Cardiovascular, Chronic",Drug
"Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer",Rejected,2016-04-27,"Topotecan,_pegylated_liposomal_doxorubicin_hydrochloride,_paclitaxel,_trabectedin_and_gemcitabine_for_treating_recurrent_ovarian_cancer.pdf",,"Obstetrics/Gynaecology, Cancer",Drug
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis,Rejected,2016-03-23,Ruxolitinib_for_treating_disease-related_splenomegaly_or_symptoms_in_adults_with_myelofibrosis.pdf,,"Chronic, Rare Disease (Orphan Drugs)",Drug
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer),Rejected,2001-04-26,Guidance_on_the_use_of_temozolomide_for_the_treatment_of_recurrent_malignant_glioma_(brain_cancer).pdf,,"Nervous System, Cancer",Drug
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia,Approved,2016-02-24,Ezetimibe_for_treating_primary_heterozygous-familial_and_non-familial_hypercholesterolaemia.pdf,,"Cardiovascular, Chronic",Drug
Nivolumab for treating advanced (unresectable or metastatic) melanoma,Approved,2016-02-18,Nivolumab_for_treating_advanced_(unresectable_or_metastatic)_melanoma.pdf,2015-08,Cancer,Drug
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis,Conditional,2016-02-01,TNF-alpha_inhibitors_for_ankylosing_spondylitis_and_non-radiographic_axial_spondyloarthritis.pdf,,"Chronic, Musculoskeletal diseases",Drug
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Approved,2016-01-27,Enzalutamide_for_treating_metastatic_hormone-relapsed_prostate_cancer_before_chemotherapy_is_indicated.pdf,,Cancer,Drug
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,Rejected,2016-01-27,Ramucirumab_for_treating_advanced_gastric_cancer_or_gastro–oesophageal_junction_adenocarcinoma_previously_treated_with_chemotherapy.pdf,,Cancer,Drug
Nintedanib for treating idiopathic pulmonary fibrosis,Rejected,2016-01-27,Nintedanib_for_treating_idiopathic_pulmonary_fibrosis.pdf,,Rare Disease (Orphan Drugs),Drug
Panobinostat for treating multiple myeloma after at least 2 previous treatments,Approved,2016-01-27,Panobinostat_for_treating_multiple_myeloma_after_at_least_2_previous_treatments.pdf,,Cancer,Drug
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal),Rejected,2016-01-27,Eltrombopag_for_treating_severe_aplastic_anaemia_refractory_to_immunosuppressive_therapy_(terminated_appraisal).pdf,,Rare Disease (Orphan Drugs),Drug
"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed",Rejected,2016-01-26,"Adalimumab,_etanercept,_infliximab,_certolizumab_pegol,_golimumab,_tocilizumab_and_abatacept_for_rheumatoid_arthritis_not_previously_treated_with_DMARDs_or_after_conventional_DMARDs_only_have_failed.pdf",,Musculoskeletal diseases,Drug
Guidance on the use of imatinib for chronic myeloid leukaemia,Approved,2003-10-22,Guidance_on_the_use_of_imatinib_for_chronic_myeloid_leukaemia.pdf,,"Chronic, Cancer",Drug
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears,Approved,2015-12-16,Ciclosporin_for_treating_dry_eye_disease_that_has_not_improved_despite_treatment_with_artificial_tears.pdf,,Chronic,Drug
Bortezomib for previously untreated mantle cell lymphoma,Approved,2015-12-16,Bortezomib_for_previously_untreated_mantle_cell_lymphoma.pdf,,Cancer,Drug
"Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis",Approved,2015-12-16,"Abatacept,_adalimumab,_etanercept_and_tocilizumab_for_treating_juvenile_idiopathic_arthritis.pdf",,Musculoskeletal diseases,Drug
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy,Rejected,2015-12-16,Erlotinib_and_gefitinib_for_treating_non-small-cell_lung_cancer_that_has_progressed_after_prior_chemotherapy.pdf,,Cancer,Drug
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C,Conditional,2015-11-25,Ombitasvir–paritaprevir–ritonavir_with_or_without_dasabuvir_for_treating_chronic_hepatitis_C.pdf,,Chronic,Drug
Vortioxetine for treating major depressive episodes,Rejected,2015-11-25,Vortioxetine_for_treating_major_depressive_episodes.pdf,,Nervous System,Drug
Ledipasvir–sofosbuvir for treating chronic hepatitis C,Rejected,2015-11-25,Ledipasvir–sofosbuvir_for_treating_chronic_hepatitis_C.pdf,,Chronic,Drug
Tolvaptan for treating autosomal dominant polycystic kidney disease,Rejected,2015-10-28,Tolvaptan_for_treating_autosomal_dominant_polycystic_kidney_disease.pdf,,"Chronic, Urinary-Track Diseases, Rare Disease (Orphan Drugs)",Drug
Idelalisib for treating chronic lymphocytic leukaemia,Rejected,2015-10-28,Idelalisib_for_treating_chronic_lymphocytic_leukaemia.pdf,,Cancer,Drug
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal),Rejected,2015-10-28,Paclitaxel_as_albumin-bound_nanoparticles_with_carboplatin_for_untreated_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy,Rejected,2015-08-26,Vedolizumab_for_treating_moderately_to_severely_active_Crohn's_disease_after_prior_therapy.pdf,,Chronic,Drug
"Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)",Rejected,2015-08-26,"Bevacizumab_for_treating_relapsed,_platinum‑resistant_epithelial_ovarian,_fallopian_tube_or_primary_peritoneal_cancer_(terminated_appraisal).pdf",,"Cancer, Obstetrics/Gynaecology",Drug
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism,Approved,2015-08-26,Edoxaban_for_treating_and_for_preventing_deep_vein_thrombosis_and_pulmonary_embolism.pdf,,Cardiovascular,Drug
Naloxegol for treating opioid‑induced constipation,Approved,2015-07-22,Naloxegol_for_treating_opioid‑induced_constipation.pdf,,Nervous System,Drug
Aflibercept for treating diabetic macular oedema,Rejected,2015-07-22,Aflibercept_for_treating_diabetic_macular_oedema.pdf,,Chronic,Drug
"Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",Conditional,2015-07-22,"Nintedanib_for_previously_treated_locally_advanced,_metastatic,_or_locally_recurrent_non‑small‑cell_lung_cancer.pdf",,Cancer,Drug
Everolimus for preventing organ rejection in liver transplantation,Rejected,2015-07-22,Everolimus_for_preventing_organ_rejection_in_liver_transplantation.pdf,,Rare Disease (Orphan Drugs),Drug
Secukinumab for treating moderate to severe plaque psoriasis,Rejected,2015-07-22,Secukinumab_for_treating_moderate_to_severe_plaque_psoriasis.pdf,,Musculoskeletal diseases,Drug
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal),Rejected,2015-07-22,Cangrelor_for_reducing_atherothrombotic_events_in_people_undergoing_percutaneous_coronary_intervention_or_awaiting_surgery_requiring_interruption_of_anti‑platelet_therapy_(terminated_appraisal).pdf,,Cardiovascular,Drug
Omalizumab for previously treated chronic spontaneous urticaria,Rejected,2015-06-08,Omalizumab_for_previously_treated_chronic_spontaneous_urticaria.pdf,,Chronic,Drug
Vedolizumab for treating moderately to severely active ulcerative colitis,Conditional,2015-06-05,Vedolizumab_for_treating_moderately_to_severely_active_ulcerative_colitis.pdf,,Chronic,Drug
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Approved,2015-06-04,Apixaban_for_the_treatment_and_secondary_prevention_of_deep_vein_thrombosis_and/or_pulmonary_embolism.pdf,,Cardiovascular,Drug
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia,Rejected,2015-06-02,Obinutuzumab_in_combination_with_chlorambucil_for_untreated_chronic_lymphocytic_leukaemia.pdf,,"Chronic, Cancer",Drug
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome,Approved,2015-03-25,Rivaroxaban_for_preventing_adverse_outcomes_after_acute_management_of_acute_coronary_syndrome.pdf,,Cardiovascular,Drug
Empagliflozin in combination therapy for treating type 2 diabetes,Rejected,2015-03-25,Empagliflozin_in_combination_therapy_for_treating_type 2 diabetes.pdf,,Chronic,Drug
Rifaximin for preventing episodes of overt hepatic encephalopathy,Approved,2015-03-25,Rifaximin_for_preventing_episodes_of_overt_hepatic_encephalopathy.pdf,,"Chronic, Nervous System",Drug
"Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy",Conditional,2015-02-25,"Infliximab,_adalimumab_and_golimumab_for_treating_moderately_to_severely_active_ulcerative_colitis_after_the_failure_of_conventional_therapy.pdf",,Chronic,Drug
Sofosbuvir for treating chronic hepatitis C,Rejected,2015-02-25,Sofosbuvir_for_treating_chronic_hepatitis C.pdf,,Chronic,Drug
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment,Conditional,2015-02-25,Axitinib_for_treating_advanced_renal_cell_carcinoma_after_failure_of_prior_systemic_treatment.pdf,,Cancer,Drug
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal),Rejected,2015-02-25,Regorafenib_for_metastatic_colorectal_cancer_after_treatment_for_metastatic_disease_(terminated_appraisal).pdf,,Cancer,Drug
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma,Conditional,2012-12-12,Vemurafenib_for_treating_locally_advanced_or_metastatic_BRAF V600_mutation‑positive_malignant_melanoma.pdf,,Cancer,Drug
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Approved,2014-12-17,Dabigatran_etexilate_for_the_treatment_and_secondary_prevention_of_deep_vein_thrombosis_and/or_pulmonary_embolism.pdf,,Cardiovascular,Drug
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy,Rejected,2014-11-26,Erythropoiesis‑stimulating_agents_(epoetin_and_darbepoetin)_for_treating_anaemia_in_people_with_cancer_having_chemotherapy.pdf,,Cancer,Drug
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block,Rejected,2014-11-26,Dual‑chamber_pacemakers_for_symptomatic_bradycardia_due_to_sick_sinus_syndrome_without_atrioventricular_block.pdf,,"Cardiovascular, Chronic",Medical Device
Nalmefene for reducing alcohol consumption in people with alcohol dependence,Approved,2014-11-26,Nalmefene_for_reducing_alcohol_consumption_in_people_with_alcohol_dependence.pdf,,Chronic,Drug
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours,Rejected,2014-11-26,Imatinib_for_the_adjuvant_treatment_of_gastrointestinal_stromal_tumours.pdf,,Cancer,Drug
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block,Approved,2005-02-23,Dual‑chamber_pacemakers_for_symptomatic_bradycardia_due_to_sick_sinus_syndrome_and/or_atrioventricular_block.pdf,,Cardiovascular,Medical Device
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma,Conditional,2014-10-22,Dabrafenib_for_treating_unresectable_or_metastatic_BRAF V600_mutation‑positive_melanoma.pdf,,Cancer,Drug
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis,Rejected,2014-08-27,Dimethyl_fumarate_for_treating_relapsing‑remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen,Conditional,2014-07-23,Enzalutamide_for_metastatic_hormone‑relapsed_prostate_cancer_previously_treated_with_a_docetaxel‑containing_regimen.pdf,,Cancer,Drug
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes,Approved,2014-07-23,Prasugrel_with_percutaneous_coronary_intervention_for_treating_acute_coronary_syndromes.pdf,,Cardiovascular,Drug
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma,Conditional,2014-07-23,Ipilimumab_for_previously_untreated_advanced_(unresectable_or_metastatic)_melanoma.pdf,,Cancer,Drug
Canagliflozin in combination therapy for treating type 2 diabetes,Rejected,2014-06-25,Canagliflozin_in_combination_therapy_for_treating_type 2_diabetes.pdf,,Chronic,Drug
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure,Rejected,2014-06-25,Implantable_cardioverter_defibrillators_and_cardiac_resynchronisation_therapy_for_arrhythmias_and_heart_failure.pdf,,"Cardiovascular, Chronic",Medical Device
Teriflunomide for treating relapsing–remitting multiple sclerosis,Rejected,2014-01-22,Teriflunomide_for_treating_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,Conditional,2014-04-23,Afatinib_for_treating_epidermal_growth_factor_receptor_mutation-positive_locally_advanced_or_metastatic_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,Approved,2014-04-23,Bortezomib_for_induction_therapy_in_multiple_myeloma_before_high-dose_chemotherapy_and_autologous_stem_cell_transplantation.pdf,,Cancer,Drug
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis,Rejected,2014-03-26,Rituximab_in_combination_with_glucocorticoids_for_treating_anti-neutrophil_cytoplasmic_antibody-associated_vasculitis.pdf,,Rare Disease (Orphan Drugs),Drug
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy,Rejected,2014-03-25,Aflibercept_in_combination_with_irinotecan_and_fluorouracil-based_therapy_for_treating_metastatic_colorectal_cancer_that_has_progressed_following_prior_oxaliplatin-based_chemotherapy.pdf,,Cancer,Drug
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip,Conditional,2014-02-26,Total_hip_replacement_and_resurfacing_arthroplasty_for_end-stage_arthritis_of_the_hip.pdf,,Musculoskeletal diseases,Medical Device
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion,Conditional,2014-02-26,Aflibercept_for_treating_visual_impairment_caused_by_macular_oedema_secondary_to_central_retinal_vein_occlusion.pdf,,Nervous System,Drug
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma,Rejected,2014-02-26,Pixantrone_monotherapy_for_treating_multiply_relapsed_or_refractory_aggressive_non-Hodgkin's_B‑cell_lymphoma.pdf,,Cancer,Drug
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people,Approved,2013-11-27,Peginterferon_alfa_and_ribavirin_for_treating_chronic_hepatitis C_in_children_and_young_people.pdf,,Chronic,Drug
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal),Rejected,2013-11-27,Canakinumab_for_treating_systemic_juvenile_idiopathic_arthritis_(terminated_appraisal).pdf,,Musculoskeletal diseases,Drug
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C,Approved,2006-08-23,Peginterferon_alfa_and_ribavirin_for_the_treatment_of_mild_chronic_hepatitis_C.pdf,,Chronic,Drug
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C,Approved,2004-01-28,Interferon_alfa_(pegylated_and_non-pegylated)_and_ribavirin_for_the_treatment_of_chronic_hepatitis_C.pdf,,Chronic,Drug
Pazopanib for the first-line treatment of advanced renal cell carcinoma,Approved,2011-02-23,Pazopanib_for_the_first-line_treatment_of_advanced_renal_cell_carcinoma.pdf,,Cancer,Drug
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder,Approved,2013-07-24,Aripiprazole_for_treating_moderate_to_severe_manic_episodes_in_adolescents_with_bipolar_I_disorder.pdf,,Nervous System,Drug
Aflibercept solution for injection for treating wet age‑related macular degeneration,Conditional,2013-07-24,Aflibercept_solution_for_injection_for_treating_wet_age‑related_macular_degeneration.pdf,,Nervous System,Drug
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism,Approved,2013-06-26,Rivaroxaban_for_treating_pulmonary_embolism_and_preventing_recurrent_venous_thromboembolism.pdf,,Cardiovascular,Drug
Mirabegron for treating symptoms of overactive bladder,Rejected,2013-06-26,Mirabegron_for_treating_symptoms_of_overactive_bladder.pdf,,Urinary-Track Diseases,Drug
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer,Rejected,2013-05-22,Bevacizumab_in_combination_with_paclitaxel_and_carboplatin_for_first-line_treatment_of_advanced_ovarian_cancer.pdf,,"Cancer, Obstetrics/Gynaecology",Drug
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer,Rejected,2013-05-22,Bevacizumab_in_combination_with_gemcitabine_and_carboplatin_for_treating_the_first_recurrence_of_platinum-sensitive_advanced_ovarian_cancer.pdf,,"Cancer, Obstetrics/Gynaecology",Drug
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal),Rejected,2013-05-22,Loxapine_inhalation_for_treating_acute_agitation_and_disturbed_behaviours_associated_with_schizophrenia_and_bipolar_disorder_(terminated_appraisal).pdf,,Nervous System,Drug
Omalizumab for treating severe persistent allergic asthma,Conditional,2013-04-24,Omalizumab_for_treating_severe_persistent_allergic_asthma.pdf,,Chronic,Drug
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures,Rejected,2013-04-24,Percutaneous_vertebroplasty_and_percutaneous_balloon_kyphoplasty_for_treating_osteoporotic_vertebral_compression_fractures.pdf,,Musculoskeletal diseases,Medical Device
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis,Rejected,2013-03-27,Colistimethate_sodium_and_tobramycin_dry_powders_for_inhalation_for_treating_pseudomonas_lung_infection_in_cystic_fibrosis.pdf,,Rare Disease (Orphan Drugs),Drug
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal),Rejected,2013-03-27,Methylnaltrexone_for_treating_opioid-induced_bowel_dysfunction_in_people_with_advanced_illness_receiving_palliative_care_(terminated_appraisal).pdf,,Chronic,Drug
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract,Rejected,2013-01-23,Vinflunine_for_the_treatment_of_advanced_or_metastatic_transitional_cell_carcinoma_of_the_urothelial_tract.pdf,,"Cancer, Urinary-Track Diseases",Drug
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal),Rejected,2013-01-23,Tadalafil_for_the_treatment_of_symptoms_associated_with_benign_prostatic_hyperplasia_(terminated_appraisal).pdf,,Urinary-Track Diseases,Drug
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma,Conditional,2012-12-12,Ipilimumab_for_previously_treated_advanced_(unresectable_or_metastatic)_melanoma.pdf,,Cancer,Drug
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal),Rejected,2012-12-12,Decitabine_for_the_treatment_of_acute_myeloid_leukaemia_(terminated_appraisal).pdf,,Cancer,Drug
Dronedarone for the treatment of non-permanent atrial fibrillation,Approved,2010-08-25,Dronedarone_for_the_treatment_of_non-permanent_atrial_fibrillation.pdf,,Cardiovascular,Drug
Mannitol dry powder for inhalation for treating cystic fibrosis,Approved,2012-11-28,Mannitol_dry_powder_for_inhalation_for_treating_cystic_fibrosis.pdf,,Rare Disease (Orphan Drugs),Drug
Ivabradine for treating chronic heart failure,Approved,2012-11-28,Ivabradine_for_treating_chronic_heart_failure.pdf,,"Cardiovascular, Chronic",Drug
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours,Rejected,2012-10-24,Denosumab_for_the_prevention_of_skeletal-related_events_in_adults_with_bone_metastases_from_solid_tumours.pdf,,Cancer,Drug
Alteplase for treating acute ischaemic stroke,Approved,2012-09-26,Alteplase_for_treating_acute_ischaemic_stroke.pdf,,"Cardiovascular, Nervous System",Drug
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer,Rejected,2012-08-22,Bevacizumab_in_combination_with_capecitabine_for_the_first-line_treatment_of_metastatic_breast_cancer.pdf,,Cancer,Drug
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,Approved,2012-07-25,Rivaroxaban_for_the_treatment_of_deep_vein_thrombosis_and_prevention_of_recurrent_deep_vein_thrombosis_and_pulmonary_embolism.pdf,,Cardiovascular,Drug
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer,Approved,2012-06-27,Erlotinib_for_the_first-line_treatment_of_locally_advanced_or_metastatic_EGFR-TK_mutation-positive_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine,Rejected,2012-06-27,Botulinum_toxin_type A_for_the_prevention_of_headaches_in_adults_with_chronic_migraine.pdf,,"Chronic, Nervous System",Drug
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2,Rejected,2012-06-27,Lapatinib_or_trastuzumab_in_combination_with_an_aromatase_inhibitor_for_the_first-line_treatment_of_metastatic_hormone_receptor-positive_breast_cancer_that_overexpresses_HER2.pdf,,Cancer,Drug
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation,Approved,2012-05-23,Rivaroxaban_for_the_prevention_of_stroke_and_systemic_embolism_in_people_with_atrial_fibrillation.pdf,,"Cardiovascular, Chronic",Drug
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis,Conditional,2012-04-25,Fingolimod_for_the_treatment_of_highly_active_relapsing–remitting_multiple_sclerosis.pdf,,Nervous System,Drug
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation,Approved,2012-03-15,Dabigatran_etexilate_for_the_prevention_of_stroke_and_systemic_embolism_in_atrial_fibrillation.pdf,,Cardiovascular,Drug
Pharmalgen for the treatment of bee and wasp venom allergy,Approved,2012-02-22,Pharmalgen_for_the_treatment_of_bee_and_wasp_venom_allergy.pdf,,Rare Disease (Orphan Drugs),Drug
Tocilizumab for the treatment of rheumatoid arthritis,Approved,2012-02-22,Tocilizumab_for_the_treatment_of_rheumatoid_arthritis.pdf,,Musculoskeletal diseases,Drug
Rituximab for the first-line treatment of stage III-IV follicular lymphoma,Rejected,2012-01-25,Rituximab_for_the_first-line_treatment_of_stage_III-IV_follicular_lymphoma.pdf,,Cancer,Drug
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults,Approved,2012-01-25,Apixaban_for_the_prevention_of_venous_thromboembolism_after_total_hip_or_knee_replacement_in_adults.pdf,,Cardiovascular,Drug
"Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy",Rejected,2012-01-25,"Cetuximab,_bevacizumab_and_panitumumab_for_the_treatment_of_metastatic_colorectal_cancer_after_first-line_chemotherapy.pdf",,Cancer,Drug
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer,Rejected,2007-01-24,Bevacizumab_and_cetuximab_for_the_treatment_of_metastatic_colorectal_cancer.pdf,,Cancer,Drug
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis,Rejected,2011-12-14,Tocilizumab_for_the_treatment_of_systemic_juvenile_idiopathic_arthritis.pdf,,Musculoskeletal diseases,Drug
Fulvestrant for the treatment of locally advanced or metastatic breast cancer,Rejected,2011-12-14,Fulvestrant_for_the_treatment_of_locally_advanced_or_metastatic_breast_cancer.pdf,,Cancer,Drug
Mifamurtide for the treatment of osteosarcoma,Approved,2011-10-26,Mifamurtide_for_the_treatment_of_osteosarcoma.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Ticagrelor for the treatment of acute coronary syndromes,Approved,2011-10-26,Ticagrelor_for_the_treatment_of_acute_coronary_syndromes.pdf,,Cardiovascular,Drug
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma,Approved,2011-07-27,Bortezomib_and_thalidomide_for_the_first‑line_treatment_of_multiple_myeloma.pdf,,Cancer,Drug
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion,Approved,2011-07-27,Dexamethasone_intravitreal_implant_for_the_treatment_of_macular_oedema_secondary_to_retinal_vein_occlusion.pdf,,Chronic,Drug
Agomelatine for the treatment of major depressive episodes (terminated appraisal),Rejected,2011-07-27,Agomelatine_for_the_treatment_of_major_depressive_episodes_(terminated_appraisal).pdf,,Nervous System,Drug
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction,Approved,2003-11-26,Myocardial_perfusion_scintigraphy_for_the_diagnosis_and_management_of_angina_and_myocardial_infarction.pdf,,Cardiovascular,Medical Device
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer,Rejected,2011-06-29,Erlotinib_monotherapy_for_maintenance_treatment_of_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs,Approved,2011-06-22,Golimumab_for_the_treatment_of_rheumatoid_arthritis_after_the_failure_of_previous_disease-modifying_anti-rheumatic_drugs.pdf,,"Chronic, Musculoskeletal diseases",Drug
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma,Approved,2011-06-22,Rituximab_for_the_first-line_maintenance_treatment_of_follicular_non-Hodgkin's_lymphoma.pdf,,Cancer,Drug
"Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease",Rejected,2011-05-25,"Cilostazol,_naftidrofuryl_oxalate,_pentoxifylline_and_inositol_nicotinate_for_the_treatment_of_intermittent_claudication_in_people_with_peripheral_arterial_disease.pdf",,"Cardiovascular, Chronic",Drug
Golimumab for the treatment of psoriatic arthritis,Conditional,2011-04-27,Golimumab_for_the_treatment_of_psoriatic_arthritis.pdf,,Musculoskeletal diseases,Drug
"Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",Approved,2011-03-23,"Azacitidine_for_the_treatment_of_myelodysplastic_syndromes,_chronic_myelomonocytic_leukaemia_and_acute_myeloid_leukaemia.pdf",,Cancer,Drug
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer,Rejected,2011-02-23,Bevacizumab_in_combination_with_a_taxane_for_the_first-line_treatment_of_metastatic_breast_cancer.pdf,,Cancer,Drug
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia,Approved,2011-02-23,Bendamustine_for_the_first-line_treatment_of_chronic_lymphocytic_leukaemia.pdf,,Cancer,Drug
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years,Approved,2011-01-26,Aripiprazole_for_the_treatment_of_schizophrenia_in_people_aged_15 to 17 years.pdf,,Nervous System,Drug
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events,Conditional,2010-12-15,Clopidogrel_and_modified-release_dipyridamole_for_the_prevention_of_occlusive_vascular_events.pdf,,Cardiovascular,Drug
Prucalopride for the treatment of chronic constipation in women,Approved,2010-12-15,Prucalopride_for_the_treatment_of_chronic_constipation_in_women.pdf,,Chronic,Drug
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer,Rejected,2010-12-15,Bevacizumab_in_combination_with_oxaliplatin_and_either_fluorouracil_plus_folinic_acid_or_capecitabine_for_the_treatment_of_metastatic_colorectal_cancer.pdf,,Cancer,Drug
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer,Approved,2010-11-24,Trastuzumab_for_the_treatment_of_HER2-positive_metastatic_gastric_cancer.pdf,,Cancer,Drug
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours,Rejected,2010-11-24,Imatinib_for_the_treatment_of_unresectable_and/or_metastatic_gastrointestinal_stromal_tumours.pdf,,Cancer,Drug
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours,Rejected,2004-10-27,Imatinib_for_the_treatment_of_unresectable_and/or_metastatic_gastro-intestinal_stromal_tumours.pdf,,Cancer,Drug
Denosumab for the prevention of osteoporotic fractures in postmenopausal women,Approved,2010-10-27,Denosumab_for_the_prevention_of_osteoporotic_fractures_in_postmenopausal_women.pdf,,"Chronic, Musculoskeletal diseases",Drug
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal),Rejected,2010-10-27,Bendamustine_for_the_treatment_of_indolent_(low_grade)_non-Hodgkin's_lymphoma_that_is_refractory_to_rituximab_(terminated_appraisal).pdf,,Cancer,Drug
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal),Rejected,2010-10-27,Temsirolimus_for_the_treatment_of_relapsed_or_refractory_mantle_cell_lymphoma_(terminated_appraisal).pdf,,Cancer,Drug
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C,Approved,2010-09-22,Peginterferon_alfa_and_ribavirin_for_the_treatment_of_chronic_hepatitis_C.pdf,,Chronic,Drug
"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor",Conditional,2010-08-25,"Adalimumab,_etanercept,_infliximab,_rituximab_and_abatacept_for_the_treatment_of_rheumatoid_arthritis_after_the_failure_of_a_TNF_inhibitor.pdf",,"Chronic, Musculoskeletal diseases",Drug
"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis",Rejected,2010-08-25,"Etanercept,_infliximab_and_adalimumab_for_the_treatment_of_psoriatic_arthritis.pdf",,"Chronic, Musculoskeletal diseases",Drug
Capecitabine for the treatment of advanced gastric cancer,Approved,2010-07-28,Capecitabine_for_the_treatment_of_advanced_gastric_cancer.pdf,,Cancer,Drug
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer,Approved,2010-07-28,Gefitinib_for_the_first-line_treatment_of_locally_advanced_or_metastatic_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia,Approved,2010-07-28,Rituximab_for_the_treatment_of_relapsed_or_refractory_chronic_lymphocytic_leukaemia.pdf,,Cancer,Drug
Human growth hormone (somatropin) for the treatment of growth failure in children,Approved,2010-05-26,Human_growth_hormone_(somatropin)_for_the_treatment_of_growth_failure_in_children.pdf,,Rare Disease (Orphan Drugs),Drug
Infliximab and adalimumab for the treatment of Crohn's disease,Approved,2010-05-19,Infliximab_and_adalimumab_for_the_treatment_of_Crohn's_disease.pdf,,Chronic,Drug
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes,Rejected,2002-09-05,Guidance_on_the_use_of_glycoprotein_IIb/IIIa_inhibitors_in_the_treatment_of_acute_coronary_syndromes.pdf,,Cardiovascular,Drug
Topotecan for the treatment of relapsed small-cell lung cancer,Rejected,2009-11-25,Topotecan_for_the_treatment_of_relapsed_small-cell_lung_cancer.pdf,,Cancer,Drug
Topotecan for the treatment of recurrent and stage IVB cervical cancer,Conditional,2009-10-28,Topotecan_for_the_treatment_of_recurrent_and_stage_IVB_cervical_cancer.pdf,,Cancer,Drug
Guidance on the use of electroconvulsive therapy,Approved,2003-04-26,Guidance_on_the_use_of_electroconvulsive_therapy.pdf,,Nervous System,Other treatment
Sunitinib for the treatment of gastrointestinal stromal tumours,Approved,2009-09-23,Sunitinib_for_the_treatment_of_gastrointestinal_stromal_tumours.pdf,,Cancer,Drug
Pemetrexed for the first-line treatment of non-small-cell lung cancer,Conditional,2009-09-23,Pemetrexed_for_the_first-line_treatment_of_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Alitretinoin for the treatment of severe chronic hand eczema,Approved,2009-08-26,Alitretinoin_for_the_treatment_of_severe_chronic_hand_eczema.pdf,,Chronic,Drug
"Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma",Rejected,2009-08-26,"Bevacizumab_(first-line),_sorafenib_(first-_and_second-line),_sunitinib_(second-line)_and_temsirolimus_(first-line)_for_the_treatment_of_advanced_and/or_metastatic_renal_cell_carcinoma.pdf",,Cancer,Drug
Tenofovir disoproxil for the treatment of chronic hepatitis B,Approved,2009-07-22,Tenofovir_disoproxil_for_the_treatment_of_chronic_hepatitis_B.pdf,,Chronic,Drug
Rituximab for the first-line treatment of chronic lymphocytic leukaemia,Rejected,2009-07-22,Rituximab_for_the_first-line_treatment_of_chronic_lymphocytic_leukaemia.pdf,,Cancer,Drug
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults,Approved,2009-04-22,Rivaroxaban_for_the_prevention_of_venous_thromboembolism_after_total_hip_or_total_knee_replacement_in_adults.pdf,,"Cardiovascular, Musculoskeletal diseases",Drug
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma,Approved,2009-03-25,Sunitinib_for_the_first-line_treatment_of_advanced_and/or_metastatic_renal_cell_carcinoma.pdf,,Cancer,Drug
"Amantadine, oseltamivir and zanamivir for the treatment of influenza",Rejected,2009-02-25,"Amantadine,_oseltamivir_and_zanamivir_for_the_treatment_of_influenza.pdf",,NULL,Drug
Machine perfusion systems and cold static storage of kidneys from deceased donors,Rejected,2009-01-28,Machine_perfusion_systems_and_cold_static_storage_of_kidneys_from_deceased_donors.pdf,,Urinary-Track Diseases,Medical Device
Infliximab for acute exacerbations of ulcerative colitis,Approved,2008-12-17,Infliximab_for_acute_exacerbations_of_ulcerative_colitis.pdf,,Chronic,Drug
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin,Rejected,2008-10-22,Spinal_cord_stimulation_for_chronic_pain_of_neuropathic_or_ischaemic_origin.pdf,,"Chronic, Nervous System",Medical Device
Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults,Approved,2008-09-24,Dabigatran_etexilate_for_the_prevention_of_venous_thromboembolism_after_hip_or_knee_replacement_surgery_in_adults.pdf,,Cardiovascular,Drug
"Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza",Rejected,2008-09-24,"Oseltamivir,_amantadine_(review)_and_zanamivir_for_the_prophylaxis_of_influenza.pdf",,NULL,Drug
Routine antenatal anti-D prophylaxis for women who are rhesus D negative,Approved,2008-08-27,Routine_antenatal_anti-D_prophylaxis_for_women_who_are_rhesus_D_negative.pdf,,Obstetrics/Gynaecology,Drug
Entecavir for the treatment of chronic hepatitis B,Approved,2008-08-27,Entecavir_for_the_treatment_of_chronic_hepatitis_B.pdf,,Chronic,Drug
Telbivudine for the treatment of chronic hepatitis B,Rejected,2008-08-27,Telbivudine_for_the_treatment_of_chronic_hepatitis_B.pdf,,Chronic,Drug
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus,Rejected,2008-07-23,Continuous_subcutaneous_insulin_infusion_for_the_treatment_of_diabetes_mellitus.pdf,,Chronic,Medical Device
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal),Rejected,2008-06-25,Bevacizumab_for_the_treatment_of_non-small-cell_lung_cancer_(terminated_appraisal).pdf,,Cancer,Drug
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal),Rejected,2008-06-25,Carmustine_implants_for_the_treatment_of_recurrent_glioblastoma_multiforme_(terminated_appraisal).pdf,,Cancer,Medical Device
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck,Approved,2008-06-25,Cetuximab_for_the_treatment_of_locally_advanced_squamous_cell_cancer_of_the_head_and_neck.pdf,,Cancer,Drug
Adalimumab for the treatment of adults with psoriasis,Approved,2008-06-25,Adalimumab_for_the_treatment_of_adults_with_psoriasis.pdf,,Chronic,Drug
Structural neuroimaging in first-episode psychosis,Rejected,2008-02-27,Structural_neuroimaging_in_first-episode_psychosis.pdf,,Nervous System,Medical Device
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma,Approved,2008-02-27,Rituximab_for_the_treatment_of_relapsed_or_refractory_stage_III_or_IV_follicular_non-Hodgkin's_lymphoma.pdf,,Cancer,Drug
Infliximab for the treatment of adults with psoriasis,Approved,2008-01-23,Infliximab_for_the_treatment_of_adults_with_psoriasis.pdf,,Chronic,Drug
Pemetrexed for the treatment of malignant pleural mesothelioma,Approved,2008-01-23,Pemetrexed_for_the_treatment_of_malignant_pleural_mesothelioma.pdf,,"Cancer, Rare Disease (Orphan Drugs)",Drug
Bortezomib monotherapy for relapsed multiple myeloma,Approved,2007-10-23,Bortezomib_monotherapy_for_relapsed_multiple_myeloma.pdf,,Cancer,Drug
Stapled haemorrhoidopexy for the treatment of haemorrhoids,Approved,2007-09-26,Stapled_haemorrhoidopexy_for_the_treatment_of_haemorrhoids.pdf,,Chronic,Other treatment
Pemetrexed for the treatment of non-small-cell lung cancer,Rejected,2007-08-22,Pemetrexed_for_the_treatment_of_non-small-cell_lung_cancer.pdf,,Cancer,Drug
Varenicline for smoking cessation,Approved,2007-07-25,Varenicline_for_smoking_cessation.pdf,,Chronic,Drug
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma,Rejected,2007-06-27,Carmustine_implants_and_temozolomide_for_the_treatment_of_newly_diagnosed_high-grade_glioma.pdf,,"Nervous System, Cancer",Drug
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia,Rejected,2007-02-28,Fludarabine_monotherapy_for_the_first-line_treatment_of_chronic_lymphocytic_leukaemia.pdf,,"Chronic, Cancer",Drug
Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy,Rejected,2007-01-24,Cinacalcet_for_the_treatment_of_secondary_hyperparathyroidism_in_patients_with_end-stage_renal_disease_on_maintenance_dialysis_therapy.pdf,,Chronic,Drug
Methadone and buprenorphine for the management of opioid dependence,Rejected,2007-01-24,Methadone_and_buprenorphine_for_the_management_of_opioid_dependence.pdf,,Chronic,Other treatment
Naltrexone for the management of opioid dependence,Approved,2007-01-24,Naltrexone_for_the_management_of_opioid_dependence.pdf,,Nervous System,Drug
Gemcitabine for the treatment of metastatic breast cancer,Approved,2007-01-24,Gemcitabine_for_the_treatment_of_metastatic_breast_cancer.pdf,,Cancer,Drug
Laparoscopic surgery for colorectal cancer,Approved,2006-08-23,Laparoscopic_surgery_for_colorectal_cancer.pdf,,Cancer,Medical Device
Etanercept and efalizumab for the treatment of adults with psoriasis,Rejected,2006-07-26,Etanercept_and_efalizumab_for_the_treatment_of_adults_with_psoriasis.pdf,,Chronic,Drug
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer,Rejected,2006-06-28,Docetaxel_for_the_treatment_of_hormone-refractory_metastatic_prostate_cancer.pdf,,Cancer,Drug
Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer,Rejected,2006-04-26,Capecitabine_and_oxaliplatin_in_the_adjuvant_treatment_of_stage_III_(Dukes'_C)_colon_cancer.pdf,,Cancer,Drug
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B,Approved,2006-02-22,Adefovir_dipivoxil_and_peginterferon_alfa-2a_for_the_treatment_of_chronic_hepatitis_B.pdf,,Chronic,Drug
HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries),Rejected,2005-07-27,HealOzone_for_the_treatment_of_tooth_decay_(occlusal_pit_and_fissure_caries_and_root_caries).pdf,,NULL,Medical Device
Guidance on the use of paclitaxel in the treatment of ovarian cancer,Approved,2003-01-22,Guidance_on_the_use_of_paclitaxel_in_the_treatment_of_ovarian_cancer.pdf,,Cancer,Drug
Laparoscopic surgery for inguinal hernia repair,Approved,2004-09-22,Laparoscopic_surgery_for_inguinal_hernia_repair.pdf,,NULL,Medical Device
Tacrolimus and pimecrolimus for atopic eczema,Rejected,2004-08-25,Tacrolimus_and_pimecrolimus_for_atopic_eczema.pdf,,Chronic,Drug
Frequency of application of topical corticosteroids for atopic eczema,Approved,2004-08-25,Frequency_of_application_of_topical_corticosteroids_for_atopic_eczema.pdf,,Chronic,Drug
"Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia",Approved,2004-04-28,"Guidance_on_the_use_of_zaleplon,_zolpidem_and_zopiclone_for_the_short-term_management_of_insomnia.pdf",,Nervous System,Drug
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding,Rejected,2004-04-28,Fluid-filled_thermal_balloon_and_microwave_endometrial_ablation_techniques_for_heavy_menstrual_bleeding.pdf,,Obstetrics/Gynaecology,Medical Device
Pre-hospital initiation of fluid replacement therapy in trauma,Approved,2004-01-28,Pre-hospital_initiation_of_fluid_replacement_therapy_in_trauma.pdf,,Cardiovascular,Other treatment
Guidance on the use of liquid-based cytology for cervical screening,Approved,2003-10-22,Guidance_on_the_use_of_liquid-based_cytology_for_cervical_screening.pdf,,"Obstetrics/Gynaecology, Cancer",Medical Device
Human growth hormone (somatropin) in adults with growth hormone deficiency,Conditional,2003-08-27,Human_growth_hormone_(somatropin)_in_adults_with_growth_hormone_deficiency.pdf,,Rare Disease (Orphan Drugs),Drug
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer,Approved,2003-05-27,Guidance_on_the_use_of_capecitabine_and_tegafur_with_uracil_for_metastatic_colorectal_cancer.pdf,,Cancer,Drug
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction,Approved,2002-10-30,Guidance_on_the_use_of_drugs_for_early_thrombolysis_in_the_treatment_of_acute_myocardial_infarction.pdf,,Cardiovascular,Drug
Guidance on the use of ultrasound locating devices for placing central venous catheters,Rejected,2002-10-04,Guidance_on_the_use_of_ultrasound_locating_devices_for_placing_central_venous_catheters.pdf,,NULL,Medical Device
Guidance on the use of trastuzumab for the treatment of advanced breast cancer,Approved,2002-03-15,Guidance_on_the_use_of_trastuzumab_for_the_treatment_of_advanced_breast_cancer.pdf,,Cancer,Drug
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia,Approved,2001-09-26,Guidance_on_the_use_of_fludarabine_for_B-cell_chronic_lymphocytic_leukaemia.pdf,,"Chronic, Cancer",Drug
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease,Approved,2001-01-23,Guidance_on_the_use_of_riluzole_(Rilutek)_for_the_treatment_of_motor_neurone_disease.pdf,,"Nervous System, Chronic, Rare Disease (Orphan Drugs)",Drug
Guidance on the extraction of wisdom teeth,Rejected,2000-03-27,Guidance_on_the_extraction_of_wisdom_teeth.pdf,,NULL,
